WO2020203998A1 - 両親媒性化合物、並びにこれを用いた医療用樹脂組成物および医薬品添加剤 - Google Patents
両親媒性化合物、並びにこれを用いた医療用樹脂組成物および医薬品添加剤 Download PDFInfo
- Publication number
- WO2020203998A1 WO2020203998A1 PCT/JP2020/014668 JP2020014668W WO2020203998A1 WO 2020203998 A1 WO2020203998 A1 WO 2020203998A1 JP 2020014668 W JP2020014668 W JP 2020014668W WO 2020203998 A1 WO2020203998 A1 WO 2020203998A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- carbon atoms
- polymer
- amphipathic compound
- monomer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 117
- 239000011342 resin composition Substances 0.000 title claims description 19
- 239000000546 pharmaceutical excipient Substances 0.000 title claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 106
- 239000000178 monomer Substances 0.000 claims abstract description 81
- 239000002502 liposome Substances 0.000 claims abstract description 77
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 14
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract 5
- 229920000642 polymer Polymers 0.000 claims description 125
- 150000002632 lipids Chemical class 0.000 claims description 45
- 239000000126 substance Substances 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 125000005647 linker group Chemical group 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 239000000470 constituent Substances 0.000 abstract description 13
- 239000003937 drug carrier Substances 0.000 abstract description 9
- 229920003023 plastic Polymers 0.000 abstract description 9
- 239000004033 plastic Substances 0.000 abstract description 9
- 238000001179 sorption measurement Methods 0.000 abstract description 6
- -1 polypropylene Polymers 0.000 description 64
- 150000002430 hydrocarbons Chemical group 0.000 description 63
- 125000000524 functional group Chemical group 0.000 description 47
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 46
- 238000000034 method Methods 0.000 description 44
- 239000000243 solution Substances 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- 239000003814 drug Substances 0.000 description 35
- 239000000203 mixture Substances 0.000 description 34
- 238000004519 manufacturing process Methods 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- 229940079593 drug Drugs 0.000 description 29
- 229920001223 polyethylene glycol Polymers 0.000 description 26
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000002202 Polyethylene glycol Substances 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 17
- 239000003505 polymerization initiator Substances 0.000 description 17
- 125000000217 alkyl group Chemical group 0.000 description 16
- 230000000379 polymerizing effect Effects 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 15
- 239000012986 chain transfer agent Substances 0.000 description 14
- 239000002245 particle Substances 0.000 description 14
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 13
- 238000006116 polymerization reaction Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000012546 transfer Methods 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 229910002091 carbon monoxide Inorganic materials 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 229920001515 polyalkylene glycol Polymers 0.000 description 11
- 239000004743 Polypropylene Substances 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 10
- 238000004132 cross linking Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- QJAOYSPHSNGHNC-UHFFFAOYSA-N octadecane-1-thiol Chemical compound CCCCCCCCCCCCCCCCCCS QJAOYSPHSNGHNC-UHFFFAOYSA-N 0.000 description 10
- 125000005702 oxyalkylene group Chemical group 0.000 description 10
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 10
- 229920001155 polypropylene Polymers 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 7
- 229930186217 Glycolipid Natural products 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 125000002947 alkylene group Chemical group 0.000 description 7
- QYZFTMMPKCOTAN-UHFFFAOYSA-N n-[2-(2-hydroxyethylamino)ethyl]-2-[[1-[2-(2-hydroxyethylamino)ethylamino]-2-methyl-1-oxopropan-2-yl]diazenyl]-2-methylpropanamide Chemical compound OCCNCCNC(=O)C(C)(C)N=NC(C)(C)C(=O)NCCNCCO QYZFTMMPKCOTAN-UHFFFAOYSA-N 0.000 description 7
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 7
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 6
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 6
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 229940106189 ceramide Drugs 0.000 description 6
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 125000005456 glyceride group Chemical group 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 6
- GHJOIQFPDMIKHT-UHFFFAOYSA-N propane-1,2,3-triol;prop-2-enoic acid Chemical compound OC(=O)C=C.OCC(O)CO GHJOIQFPDMIKHT-UHFFFAOYSA-N 0.000 description 6
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 6
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 5
- RKOOOVKGLHCLTP-UHFFFAOYSA-N 2-methylprop-2-enoic acid;propane-1,2,3-triol Chemical compound CC(=C)C(O)=O.OCC(O)CO RKOOOVKGLHCLTP-UHFFFAOYSA-N 0.000 description 5
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 5
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 150000003408 sphingolipids Chemical class 0.000 description 5
- 229920002554 vinyl polymer Polymers 0.000 description 5
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 125000006353 oxyethylene group Chemical group 0.000 description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 description 4
- 238000010526 radical polymerization reaction Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 229940006193 2-mercaptoethanesulfonic acid Drugs 0.000 description 3
- FYRRWGUSDSVKRL-UHFFFAOYSA-N 2-methyl-4-(3-methylbut-3-enoxy)but-1-ene Chemical compound CC(=C)CCOCCC(C)=C FYRRWGUSDSVKRL-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000002597 Solanum melongena Nutrition 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- ACIAHEMYLLBZOI-ZZXKWVIFSA-N Unsaturated alcohol Chemical compound CC\C(CO)=C/C ACIAHEMYLLBZOI-ZZXKWVIFSA-N 0.000 description 3
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010382 chemical cross-linking Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 235000003441 saturated fatty acids Nutrition 0.000 description 3
- 238000004513 sizing Methods 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940035024 thioglycerol Drugs 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- IBUKXRINTKQBRQ-KCKFLZCVSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-D-myo-inositol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O IBUKXRINTKQBRQ-KCKFLZCVSA-N 0.000 description 2
- RHODCGQMKYNKED-SXOMAYOGSA-N 1,2-dilauroyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCC RHODCGQMKYNKED-SXOMAYOGSA-N 0.000 description 2
- YFWHNAWEOZTIPI-DIPNUNPCSA-N 1,2-dioctadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCCCC YFWHNAWEOZTIPI-DIPNUNPCSA-N 0.000 description 2
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-trimethylbenzene Chemical compound CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 2
- UICXTANXZJJIBC-UHFFFAOYSA-N 1-(1-hydroperoxycyclohexyl)peroxycyclohexan-1-ol Chemical compound C1CCCCC1(O)OOC1(OO)CCCCC1 UICXTANXZJJIBC-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- STCQKDIKPYGUTO-UHFFFAOYSA-N 2,2-dimethylpent-3-enamide Chemical compound CC=CC(C)(C)C(N)=O STCQKDIKPYGUTO-UHFFFAOYSA-N 0.000 description 2
- JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 2
- WYGWHHGCAGTUCH-UHFFFAOYSA-N 2-[(2-cyano-4-methylpentan-2-yl)diazenyl]-2,4-dimethylpentanenitrile Chemical compound CC(C)CC(C)(C#N)N=NC(C)(C#N)CC(C)C WYGWHHGCAGTUCH-UHFFFAOYSA-N 0.000 description 2
- SLKDGVPOSSLUAI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(hexadecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-UHFFFAOYSA-N 0.000 description 2
- ZLGYVWRJIZPQMM-HHHXNRCGSA-N 2-azaniumylethyl [(2r)-2,3-di(dodecanoyloxy)propyl] phosphate Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCC ZLGYVWRJIZPQMM-HHHXNRCGSA-N 0.000 description 2
- NMZSJIQGMAGSSO-UHFFFAOYSA-N 3-[[1-amino-2-[[1-amino-1-(2-carboxyethylimino)-2-methylpropan-2-yl]diazenyl]-2-methylpropylidene]amino]propanoic acid Chemical compound OC(=O)CCNC(=N)C(C)(C)N=NC(C)(C)C(=N)NCCC(O)=O NMZSJIQGMAGSSO-UHFFFAOYSA-N 0.000 description 2
- VFXXTYGQYWRHJP-UHFFFAOYSA-N 4,4'-azobis(4-cyanopentanoic acid) Chemical compound OC(=O)CCC(C)(C#N)N=NC(C)(CCC(O)=O)C#N VFXXTYGQYWRHJP-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KLFKZIQAIPDJCW-HTIIIDOHSA-N Dipalmitoylphosphatidylserine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-HTIIIDOHSA-N 0.000 description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- YYDKLWXTBUGVFX-UHFFFAOYSA-N N(=NC(C(=O)NCCO)(C)OC)C(C(=O)NCCO)(C)OC Chemical compound N(=NC(C(=O)NCCO)(C)OC)C(C(=O)NCCO)(C)OC YYDKLWXTBUGVFX-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 2
- KKOSJVWUOHEQKA-HSZRJFAPSA-N PE(10:0/10:0) Chemical compound CCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCC KKOSJVWUOHEQKA-HSZRJFAPSA-N 0.000 description 2
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- FQZQXPXKJFOAGE-KICCZPNWSA-N [(2r)-3-[hydroxy-[(5r)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-2-octadecanoyloxypropyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)OC1C(O)C(O)C(O)[C@@H](O)C1O FQZQXPXKJFOAGE-KICCZPNWSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Natural products CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 239000005456 alcohol based solvent Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical group 0.000 description 2
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- LBSPZZSGTIBOFG-UHFFFAOYSA-N bis[2-(4,5-dihydro-1h-imidazol-2-yl)propan-2-yl]diazene;dihydrochloride Chemical compound Cl.Cl.N=1CCNC=1C(C)(C)N=NC(C)(C)C1=NCCN1 LBSPZZSGTIBOFG-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-O cysteaminium Chemical compound [NH3+]CCS UFULAYFCSOUIOV-UHFFFAOYSA-O 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 2
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 2
- LHCZDUCPSRJDJT-UHFFFAOYSA-N dilauroyl phosphatidylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCC LHCZDUCPSRJDJT-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- WNAHIZMDSQCWRP-UHFFFAOYSA-N dodecane-1-thiol Chemical compound CCCCCCCCCCCCS WNAHIZMDSQCWRP-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000002327 glycerophospholipids Chemical class 0.000 description 2
- 125000003827 glycol group Chemical group 0.000 description 2
- NDJKXXJCMXVBJW-UHFFFAOYSA-N heptadecane Chemical compound CCCCCCCCCCCCCCCCC NDJKXXJCMXVBJW-UHFFFAOYSA-N 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- QNVRIHYSUZMSGM-UHFFFAOYSA-N hexan-2-ol Chemical compound CCCCC(C)O QNVRIHYSUZMSGM-UHFFFAOYSA-N 0.000 description 2
- ZOCHHNOQQHDWHG-UHFFFAOYSA-N hexan-3-ol Chemical compound CCCC(O)CC ZOCHHNOQQHDWHG-UHFFFAOYSA-N 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- CPJRRXSHAYUTGL-UHFFFAOYSA-N isopentenyl alcohol Chemical compound CC(=C)CCO CPJRRXSHAYUTGL-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 238000010550 living polymerization reaction Methods 0.000 description 2
- 229960003151 mercaptamine Drugs 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- BUGISVZCMXHOHO-UHFFFAOYSA-N n-[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]-2-[[1-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]diazenyl]-2-methylpropanamide Chemical compound OCC(CO)(CO)NC(=O)C(C)(C)N=NC(C)(C)C(=O)NC(CO)(CO)CO BUGISVZCMXHOHO-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- LQERIDTXQFOHKA-UHFFFAOYSA-N nonadecane Chemical compound CCCCCCCCCCCCCCCCCCC LQERIDTXQFOHKA-UHFFFAOYSA-N 0.000 description 2
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 2
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- YCOZIPAWZNQLMR-UHFFFAOYSA-N pentadecane Chemical compound CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 description 2
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 150000008103 phosphatidic acids Chemical class 0.000 description 2
- 229940067626 phosphatidylinositols Drugs 0.000 description 2
- 150000008106 phosphatidylserines Chemical class 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001748 polybutylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 229940071643 prefilled syringe Drugs 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 239000007870 radical polymerization initiator Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- RBBWNXJFTBCLKT-UHFFFAOYSA-M sodium;ethanethioate Chemical compound [Na+].CC([S-])=O RBBWNXJFTBCLKT-UHFFFAOYSA-M 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- BGHCVCJVXZWKCC-UHFFFAOYSA-N tetradecane Chemical compound CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- IIYFAKIEWZDVMP-UHFFFAOYSA-N tridecane Chemical compound CCCCCCCCCCCCC IIYFAKIEWZDVMP-UHFFFAOYSA-N 0.000 description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 description 1
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- MBZYKEVPFYHDOH-UHFFFAOYSA-N (10S)-3c-Hydroxy-4.4.10r.13t.14c-pentamethyl-17t-((R)-1.5-dimethyl-hexyl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(C)CCCC(C)C)CCC21C MBZYKEVPFYHDOH-UHFFFAOYSA-N 0.000 description 1
- RWTQCZGAMKTBRV-PTHRTHQKSA-N (1s,2r,5s,10s,11s,14r,15r)-2,15-dimethyl-14-[(2r)-6-methylheptan-2-yl]tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-en-5-yl pentanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCC)C1 RWTQCZGAMKTBRV-PTHRTHQKSA-N 0.000 description 1
- TYAQXZHDAGZOEO-UHFFFAOYSA-N (2-octadecanoyloxy-3-tetradecanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCC TYAQXZHDAGZOEO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- FROLUYNBHPUZQU-IIZJPUEISA-N (2R,3R,4S,5R)-2-(hydroxymethyl)-6-[3-[3-[(3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropoxy]propoxy]oxane-3,4,5-triol Chemical compound OC[C@H]1OC(OCCCOCCCOC2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O FROLUYNBHPUZQU-IIZJPUEISA-N 0.000 description 1
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- UFSKIYBOKFBSOA-MLYSRARTSA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-octadecoxyoxane-3,4,5-triol Chemical compound CCCCCCCCCCCCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UFSKIYBOKFBSOA-MLYSRARTSA-N 0.000 description 1
- ORUDEUCNYHCHPB-OUUBHVDSSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-tetradecoxyoxane-3,4,5-triol Chemical compound CCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ORUDEUCNYHCHPB-OUUBHVDSSA-N 0.000 description 1
- NMRPBPVERJPACX-UHFFFAOYSA-N (3S)-octan-3-ol Natural products CCCCCC(O)CC NMRPBPVERJPACX-UHFFFAOYSA-N 0.000 description 1
- IZVFFXVYBHFIHY-UHFFFAOYSA-N (3alpha, 5alpha)-Cholest-7-en-3-ol, 9CI Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CCC21 IZVFFXVYBHFIHY-UHFFFAOYSA-N 0.000 description 1
- PKEPPDGGTSZLBL-UHFFFAOYSA-N (3beta, 5alpha, 22E)-Cholesta-7, 22-dien-3-ol, 9CI Natural products C1C(O)CCC2(C)C(CCC3(C(C(CCC=C(C)C)C)CCC33)C)C3=CCC21 PKEPPDGGTSZLBL-UHFFFAOYSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- HVYWMOMLDIMFJA-VEIPTCAHSA-N (3r,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1C=C2C[C@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-VEIPTCAHSA-N 0.000 description 1
- QGVQZRDQPDLHHV-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3-thiol Chemical compound C1C=C2C[C@@H](S)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QGVQZRDQPDLHHV-DPAQBDIFSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- MLKLDGSYMHFAOC-AREMUKBSSA-N 1,2-dicapryl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCC MLKLDGSYMHFAOC-AREMUKBSSA-N 0.000 description 1
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 description 1
- AFSHUZFNMVJNKX-LLWMBOQKSA-N 1,2-dioleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC\C=C/CCCCCCCC AFSHUZFNMVJNKX-LLWMBOQKSA-N 0.000 description 1
- WZRKSPFYXUXINF-UHFFFAOYSA-N 1-(bromomethyl)-4-methylbenzene Chemical compound CC1=CC=C(CBr)C=C1 WZRKSPFYXUXINF-UHFFFAOYSA-N 0.000 description 1
- FXCXOKOKILDXCL-UHFFFAOYSA-N 1-but-2-enoxybut-2-ene Chemical compound CC=CCOCC=CC FXCXOKOKILDXCL-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- BPIUIOXAFBGMNB-UHFFFAOYSA-N 1-hexoxyhexane Chemical compound CCCCCCOCCCCCC BPIUIOXAFBGMNB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RFVFQQWKPSOBED-PSXMRANNSA-N 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCC RFVFQQWKPSOBED-PSXMRANNSA-N 0.000 description 1
- ZPDQFUYPBVXUKS-YADHBBJMSA-N 1-stearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC[C@H](N)C(O)=O ZPDQFUYPBVXUKS-YADHBBJMSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- YRWIUNJQYGATHV-FTLVODPJSA-N 19-Hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(CO)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 YRWIUNJQYGATHV-FTLVODPJSA-N 0.000 description 1
- YRWIUNJQYGATHV-UHFFFAOYSA-N 19-hydroxycholesterol Natural products C1C=C2CC(O)CCC2(CO)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 YRWIUNJQYGATHV-UHFFFAOYSA-N 0.000 description 1
- CUDYYMUUJHLCGZ-UHFFFAOYSA-N 2-(2-methoxypropoxy)propan-1-ol Chemical compound COC(C)COC(C)CO CUDYYMUUJHLCGZ-UHFFFAOYSA-N 0.000 description 1
- WOFPPJOZXUTRAU-UHFFFAOYSA-N 2-Ethyl-1-hexanol Natural products CCCCC(O)CCC WOFPPJOZXUTRAU-UHFFFAOYSA-N 0.000 description 1
- QNVRIHYSUZMSGM-LURJTMIESA-N 2-Hexanol Natural products CCCC[C@H](C)O QNVRIHYSUZMSGM-LURJTMIESA-N 0.000 description 1
- ULIKDJVNUXNQHS-UHFFFAOYSA-N 2-Propene-1-thiol Chemical compound SCC=C ULIKDJVNUXNQHS-UHFFFAOYSA-N 0.000 description 1
- HCZMHWVFVZAHCR-UHFFFAOYSA-N 2-[2-(2-sulfanylethoxy)ethoxy]ethanethiol Chemical compound SCCOCCOCCS HCZMHWVFVZAHCR-UHFFFAOYSA-N 0.000 description 1
- TXBCBTDQIULDIA-UHFFFAOYSA-N 2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)CO TXBCBTDQIULDIA-UHFFFAOYSA-N 0.000 description 1
- HWFBTMIGWILNPM-UHFFFAOYSA-N 2-[dihydroxymethylidene(dodecyl)-lambda4-sulfanyl]acetonitrile Chemical compound CCCCCCCCCCCCS(=C(O)O)CC#N HWFBTMIGWILNPM-UHFFFAOYSA-N 0.000 description 1
- BKMMTJMQCTUHRP-UHFFFAOYSA-N 2-aminopropan-1-ol Chemical compound CC(N)CO BKMMTJMQCTUHRP-UHFFFAOYSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- QSVOWVXHKOQYIP-UHFFFAOYSA-N 2-dodecylsulfanylcarbothioylsulfanyl-2-methylpropanenitrile Chemical compound CCCCCCCCCCCCSC(=S)SC(C)(C)C#N QSVOWVXHKOQYIP-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- SVONRAPFKPVNKG-UHFFFAOYSA-N 2-ethoxyethyl acetate Chemical compound CCOCCOC(C)=O SVONRAPFKPVNKG-UHFFFAOYSA-N 0.000 description 1
- YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical compound CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 description 1
- MHXMVFDLNGKBSR-UHFFFAOYSA-N 2-hydroxyethyl 2-bromo-2-methylpropanoate Chemical compound CC(C)(Br)C(=O)OCCO MHXMVFDLNGKBSR-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical group OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- XMHDLKFMJMNOAX-UHFFFAOYSA-N 2-methyl-3-(2-methylprop-2-enoxy)prop-1-ene Chemical compound CC(=C)COCC(C)=C XMHDLKFMJMNOAX-UHFFFAOYSA-N 0.000 description 1
- RCEJCSULJQNRQQ-UHFFFAOYSA-N 2-methylbutanenitrile Chemical compound CCC(C)C#N RCEJCSULJQNRQQ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- RZPAXNJLEKLXNO-UKNNTIGFSA-N 22-Hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C(O)CCC(C)C)[C@@]1(C)CC2 RZPAXNJLEKLXNO-UKNNTIGFSA-N 0.000 description 1
- MBZYKEVPFYHDOH-BQNIITSRSA-N 24,25-dihydrolanosterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@]21C MBZYKEVPFYHDOH-BQNIITSRSA-N 0.000 description 1
- INBGSXNNRGWLJU-ZHHJOTBYSA-N 25-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)(C)O)C)[C@@]1(C)CC2 INBGSXNNRGWLJU-ZHHJOTBYSA-N 0.000 description 1
- INBGSXNNRGWLJU-UHFFFAOYSA-N 25epsilon-Hydroxycholesterin Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(CCCC(C)(C)O)C)C1(C)CC2 INBGSXNNRGWLJU-UHFFFAOYSA-N 0.000 description 1
- IWOPYKUVKWBHOT-UHFFFAOYSA-N 3,5-di(pentadecoxy)benzenecarboximidamide;hydrochloride Chemical compound Cl.CCCCCCCCCCCCCCCOC1=CC(OCCCCCCCCCCCCCCC)=CC(C(N)=N)=C1 IWOPYKUVKWBHOT-UHFFFAOYSA-N 0.000 description 1
- ZSPTYLOMNJNZNG-UHFFFAOYSA-N 3-Buten-1-ol Chemical compound OCCC=C ZSPTYLOMNJNZNG-UHFFFAOYSA-N 0.000 description 1
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 1
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 1
- UATRONWBYDQKSQ-UHFFFAOYSA-N 3-methyl-1-(3-methylbut-2-enoxy)but-2-ene Chemical compound CC(C)=CCOCC=C(C)C UATRONWBYDQKSQ-UHFFFAOYSA-N 0.000 description 1
- QRQXBVDDGHHWCA-UHFFFAOYSA-N 3-methyl-3-(2-methylbut-3-en-2-yloxy)but-1-ene Chemical compound C=CC(C)(C)OC(C)(C)C=C QRQXBVDDGHHWCA-UHFFFAOYSA-N 0.000 description 1
- ZWVXEFQIDQHWBG-UHFFFAOYSA-N 3-methyl-4-(2-methylbut-3-enoxy)but-1-ene Chemical compound C=CC(C)COCC(C)C=C ZWVXEFQIDQHWBG-UHFFFAOYSA-N 0.000 description 1
- WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- XUGISPSHIFXEHZ-UHFFFAOYSA-N 3beta-acetoxy-cholest-5-ene Natural products C1C=C2CC(OC(C)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XUGISPSHIFXEHZ-UHFFFAOYSA-N 0.000 description 1
- VICCYULHZWEWMB-UHFFFAOYSA-N 4-(1-bromoethyl)benzoic acid Chemical compound CC(Br)C1=CC=C(C(O)=O)C=C1 VICCYULHZWEWMB-UHFFFAOYSA-N 0.000 description 1
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 1
- KWSLGOVYXMQPPX-UHFFFAOYSA-N 5-[3-(trifluoromethyl)phenyl]-2h-tetrazole Chemical compound FC(F)(F)C1=CC=CC(C2=NNN=N2)=C1 KWSLGOVYXMQPPX-UHFFFAOYSA-N 0.000 description 1
- IZVFFXVYBHFIHY-SKCNUYALSA-N 5alpha-cholest-7-en-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC[C@H]21 IZVFFXVYBHFIHY-SKCNUYALSA-N 0.000 description 1
- CQSRUKJFZKVYCY-UHFFFAOYSA-N 5alpha-isofucostan-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 CQSRUKJFZKVYCY-UHFFFAOYSA-N 0.000 description 1
- LDFQZXFTCLMJBX-UHFFFAOYSA-N 6-cyano-6-propylcyclohexa-2,4-diene-1-carbothioic S-acid Chemical compound CCCC1(C=CC=CC1C(S)=O)C#N LDFQZXFTCLMJBX-UHFFFAOYSA-N 0.000 description 1
- OYXZMSRRJOYLLO-UHFFFAOYSA-N 7alpha-Hydroxycholesterol Natural products OC1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 OYXZMSRRJOYLLO-UHFFFAOYSA-N 0.000 description 1
- OYXZMSRRJOYLLO-KGZHIOMZSA-N 7beta-hydroxycholesterol Chemical compound C([C@@H]1O)=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 OYXZMSRRJOYLLO-KGZHIOMZSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- YLOZWTNBTWFBEN-UHFFFAOYSA-N C(=C)C=C(C(=O)N)CC(C)C Chemical compound C(=C)C=C(C(=O)N)CC(C)C YLOZWTNBTWFBEN-UHFFFAOYSA-N 0.000 description 1
- OTHVBWNVPSYOSU-UHFFFAOYSA-O C(C=C)(=O)OCP(=O)=C(O)C[N+](C)(C)C Chemical compound C(C=C)(=O)OCP(=O)=C(O)C[N+](C)(C)C OTHVBWNVPSYOSU-UHFFFAOYSA-O 0.000 description 1
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 1
- LWLHCZLCSDUDEL-UHFFFAOYSA-O C[N+](C)(C)CC(O)=P(=O)CCOC(=O)C=C Chemical compound C[N+](C)(C)CC(O)=P(=O)CCOC(=O)C=C LWLHCZLCSDUDEL-UHFFFAOYSA-O 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000755712 Diores Species 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- GZZPOFFXKUVNSW-UHFFFAOYSA-N Dodecenoic acid Natural products OC(=O)CCCCCCCCCC=C GZZPOFFXKUVNSW-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- QSVJYFLQYMVBDR-UHFFFAOYSA-N Ergosterin Natural products C1C(O)CCC2(C)C3=CCC4(C)C(C(C)C=CC(C)C(C)C)CCC4C3=CC=C21 QSVJYFLQYMVBDR-UHFFFAOYSA-N 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- GBBBJSKVBYJMBG-QTWVXCTBSA-N Fucosterol Natural products CC=C(CC[C@@H](C)[C@@H]1CC[C@@H]2[C@H]3C=C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3CC[C@@]12C)C(C)C GBBBJSKVBYJMBG-QTWVXCTBSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- NAACPBBQTFFYQB-UHFFFAOYSA-N Linolsaeure-cholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCC=CCCCCC)C2 NAACPBBQTFFYQB-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- BBJQPKLGPMQWBU-UHFFFAOYSA-N Palmitinsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCC)C2 BBJQPKLGPMQWBU-UHFFFAOYSA-N 0.000 description 1
- 241001662443 Phemeranthus parviflorus Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000012987 RAFT agent Substances 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- QZXMUPATKGLZAP-DXLAUQRQSA-N [(2S)-1-hexadecanoyloxy-3-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 QZXMUPATKGLZAP-DXLAUQRQSA-N 0.000 description 1
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 description 1
- MWEZHNCHKXEIBJ-ISGTVXCRSA-N [(3s,8s,10r,13r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound C1C=C2C[C@@H](OP([O-])(=O)OCC[N+](C)(C)C)CC[C@]2(C)C2[C@@H]1C1CCC([C@H](C)CCCC(C)C)[C@@]1(C)CC2 MWEZHNCHKXEIBJ-ISGTVXCRSA-N 0.000 description 1
- AVTXVDFKYBVTKR-DPAQBDIFSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] dihydrogen phosphate Chemical compound C1C=C2C[C@@H](OP(O)(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 AVTXVDFKYBVTKR-DPAQBDIFSA-N 0.000 description 1
- SUOVMGLZSOAHJY-JREUTYQLSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] icosanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCCCC)C1 SUOVMGLZSOAHJY-JREUTYQLSA-N 0.000 description 1
- LXEKPEMOWBOYRF-UHFFFAOYSA-N [2-[(1-azaniumyl-1-imino-2-methylpropan-2-yl)diazenyl]-2-methylpropanimidoyl]azanium;dichloride Chemical compound Cl.Cl.NC(=N)C(C)(C)N=NC(C)(C)C(N)=N LXEKPEMOWBOYRF-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical class [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000004808 allyl alcohols Chemical class 0.000 description 1
- WPIHMWBQRSAMDE-VPVRLJCPSA-N alpha-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-VPVRLJCPSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000010560 atom transfer radical polymerization reaction Methods 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- LWGLGSPYKZTZBM-UHFFFAOYSA-N benzenecarbonothioylsulfanyl benzenecarbodithioate Chemical compound C=1C=CC=CC=1C(=S)SSC(=S)C1=CC=CC=C1 LWGLGSPYKZTZBM-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- JMXMXKRNIYCNRV-UHFFFAOYSA-N bis(hydroxymethyl)phosphanylmethanol Chemical compound OCP(CO)CO JMXMXKRNIYCNRV-UHFFFAOYSA-N 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- ABBZJHFBQXYTLU-UHFFFAOYSA-N but-3-enamide Chemical compound NC(=O)CC=C ABBZJHFBQXYTLU-UHFFFAOYSA-N 0.000 description 1
- OVIISSOUXFJLSM-KPNWGBFJSA-N butanedioic acid;(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound OC(=O)CCC(O)=O.C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 OVIISSOUXFJLSM-KPNWGBFJSA-N 0.000 description 1
- WQAQPCDUOCURKW-UHFFFAOYSA-N butanethiol Chemical compound CCCCS WQAQPCDUOCURKW-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 1
- XUGISPSHIFXEHZ-VEVYEIKRSA-N cholesteryl acetate Chemical compound C1C=C2C[C@@H](OC(C)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 XUGISPSHIFXEHZ-VEVYEIKRSA-N 0.000 description 1
- FSMCJUNYLQOAIM-UQBZCTSOSA-N cholesteryl beta-D-glucoside Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FSMCJUNYLQOAIM-UQBZCTSOSA-N 0.000 description 1
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 1
- NAACPBBQTFFYQB-XNTGVSEISA-N cholesteryl octadeca-9,12-dienoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCC=CCC=CCCCCC)C1 NAACPBBQTFFYQB-XNTGVSEISA-N 0.000 description 1
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
- BBJQPKLGPMQWBU-JADYGXMDSA-N cholesteryl palmitate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCC)C1 BBJQPKLGPMQWBU-JADYGXMDSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- QYIXCDOBOSTCEI-NWKZBHTNSA-N coprostanol Chemical compound C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-NWKZBHTNSA-N 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- CMKBCTPCXZNQKX-UHFFFAOYSA-N cyclohexanethiol Chemical compound SC1CCCCC1 CMKBCTPCXZNQKX-UHFFFAOYSA-N 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical compound CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 description 1
- VTXVGVNLYGSIAR-UHFFFAOYSA-N decane-1-thiol Chemical compound CCCCCCCCCCS VTXVGVNLYGSIAR-UHFFFAOYSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- QSVJYFLQYMVBDR-CMNOFMQQSA-N dehydroergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@H]4C3=CC=C21 QSVJYFLQYMVBDR-CMNOFMQQSA-N 0.000 description 1
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
- 150000001985 dialkylglycerols Chemical class 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- BPHQZTVXXXJVHI-UHFFFAOYSA-N dimyristoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 1
- POXRUQZSBXFWGH-UHFFFAOYSA-L dipotassium dithionate Chemical compound [K+].[K+].[O-]S(=O)(=O)S([O-])(=O)=O POXRUQZSBXFWGH-UHFFFAOYSA-L 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000004662 dithiols Chemical class 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- UUNRYKCXJSDLRD-UHFFFAOYSA-N dodecylsulfanyl-(dodecylsulfanylcarbothioyldisulfanyl)methanethione Chemical compound CCCCCCCCCCCCSC(=S)SSC(=S)SCCCCCCCCCCCC UUNRYKCXJSDLRD-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 239000003759 ester based solvent Substances 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 125000006232 ethoxy propyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- IOLQWGVDEFWYNP-UHFFFAOYSA-N ethyl 2-bromo-2-methylpropanoate Chemical compound CCOC(=O)C(C)(C)Br IOLQWGVDEFWYNP-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- OSELKOCHBMDKEJ-JUGJNGJRSA-N fucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC\C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-JUGJNGJRSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
- GIVLTTJNORAZON-HDBOBKCLSA-N ganglioside GM2 (18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 GIVLTTJNORAZON-HDBOBKCLSA-N 0.000 description 1
- PFJKOHUKELZMLE-VEUXDRLPSA-N ganglioside GM3 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 PFJKOHUKELZMLE-VEUXDRLPSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002298 globosides Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- YXGZZOIKQLCSNC-UHFFFAOYSA-N hexadecane-1,1-dithiol Chemical compound CCCCCCCCCCCCCCCC(S)S YXGZZOIKQLCSNC-UHFFFAOYSA-N 0.000 description 1
- ORTRWBYBJVGVQC-UHFFFAOYSA-N hexadecane-1-thiol Chemical compound CCCCCCCCCCCCCCCCS ORTRWBYBJVGVQC-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- CBFCDTFDPHXCNY-UHFFFAOYSA-N icosane Chemical compound CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000012690 ionic polymerization Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000005641 methacryl group Chemical group 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- JMRZMIFDYMSZCB-UHFFFAOYSA-N morpholine-2,5-dione Chemical compound O=C1COC(=O)CN1 JMRZMIFDYMSZCB-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N n-butyl methyl ketone Natural products CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- ZQXSMRAEXCEDJD-UHFFFAOYSA-N n-ethenylformamide Chemical compound C=CNC=O ZQXSMRAEXCEDJD-UHFFFAOYSA-N 0.000 description 1
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- ZVEZMVFBMOOHAT-UHFFFAOYSA-N nonane-1-thiol Chemical group CCCCCCCCCS ZVEZMVFBMOOHAT-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940038384 octadecane Drugs 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- KZCOBXFFBQJQHH-UHFFFAOYSA-N octane-1-thiol Chemical compound CCCCCCCCS KZCOBXFFBQJQHH-UHFFFAOYSA-N 0.000 description 1
- MADOXCFISYCULS-UHFFFAOYSA-N octyl 2-sulfanylacetate Chemical compound CCCCCCCCOC(=O)CS MADOXCFISYCULS-UHFFFAOYSA-N 0.000 description 1
- SFHANYOFMGEJCT-UHFFFAOYSA-N octyl 2-sulfanylpropanoate Chemical compound CCCCCCCCOC(=O)C(C)S SFHANYOFMGEJCT-UHFFFAOYSA-N 0.000 description 1
- LWNSNYBMYBWJDN-UHFFFAOYSA-N octyl 3-sulfanylpropanoate Chemical compound CCCCCCCCOC(=O)CCS LWNSNYBMYBWJDN-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 238000006068 polycondensation reaction Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- DJEHXEMURTVAOE-UHFFFAOYSA-M potassium bisulfite Chemical compound [K+].OS([O-])=O DJEHXEMURTVAOE-UHFFFAOYSA-M 0.000 description 1
- 235000010259 potassium hydrogen sulphite Nutrition 0.000 description 1
- 229910001380 potassium hypophosphite Inorganic materials 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- CRGPNLUFHHUKCM-UHFFFAOYSA-M potassium phosphinate Chemical compound [K+].[O-]P=O CRGPNLUFHHUKCM-UHFFFAOYSA-M 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- NCNISYUOWMIOPI-UHFFFAOYSA-N propane-1,1-dithiol Chemical compound CCC(S)S NCNISYUOWMIOPI-UHFFFAOYSA-N 0.000 description 1
- KGMXPXPXPAAUMD-UHFFFAOYSA-N propane;dihydrochloride Chemical compound Cl.Cl.CCC KGMXPXPXPAAUMD-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000718 radiation-protective agent Substances 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000012712 reversible addition−fragmentation chain-transfer polymerization Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000015590 smooth muscle cell migration Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 125000004436 sodium atom Chemical group 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- CSMWJXBSXGUPGY-UHFFFAOYSA-L sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 description 1
- 229940075931 sodium dithionate Drugs 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229910001379 sodium hypophosphite Inorganic materials 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- WYKYCHHWIJXDAO-UHFFFAOYSA-N tert-butyl 2-ethylhexaneperoxoate Chemical compound CCCCC(CC)C(=O)OOC(C)(C)C WYKYCHHWIJXDAO-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- IBYFOBGPNPINBU-UHFFFAOYSA-N tetradecenoic acid Natural products CCCCCCCCCCCC=CC(O)=O IBYFOBGPNPINBU-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
- IBYFOBGPNPINBU-OUKQBFOZSA-N trans-2-tetradecenoic acid Chemical compound CCCCCCCCCCC\C=C\C(O)=O IBYFOBGPNPINBU-OUKQBFOZSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940121343 tricaprilin Drugs 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229940093633 tricaprin Drugs 0.000 description 1
- MAYCICSNZYXLHB-UHFFFAOYSA-N tricaproin Chemical compound CCCCCC(=O)OCC(OC(=O)CCCCC)COC(=O)CCCCC MAYCICSNZYXLHB-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- RHLOSBPISIVGMQ-UHFFFAOYSA-N undec-10-enyl 2-bromo-2-methylpropanoate Chemical compound CC(C)(Br)C(=O)OCCCCCCCCCC=C RHLOSBPISIVGMQ-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F20/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F20/02—Monocarboxylic acids having less than ten carbon atoms, Derivatives thereof
- C08F20/10—Esters
- C08F20/20—Esters of polyhydric alcohols or polyhydric phenols, e.g. 2-hydroxyethyl (meth)acrylate or glycerol mono-(meth)acrylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F120/10—Esters
- C08F120/20—Esters of polyhydric alcohols or polyhydric phenols, e.g. 2-hydroxyethyl (meth)acrylate or glycerol mono-(meth)acrylate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F126/06—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
- C08F126/08—N-Vinyl-pyrrolidine
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- C08L33/04—Homopolymers or copolymers of esters
- C08L33/14—Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
Definitions
- the present invention relates to an amphipathic compound, and a medical resin composition and a pharmaceutical additive using the amphipathic compound.
- DDS drug delivery system
- DDS preparation drug delivery system
- Polyethylene glycol (PEG: PolyEthylene Glycol) is widely used as a substance used in this passive targeting therapy.
- PEG-modified liposomes obtained by modifying liposomes or high molecular weight micelles with PEG are used as long-term blood-retaining liposomes as drug carriers, and a preparation containing doxorubicin (Doxorubicin (registered trademark)) is clinically used. ing.
- PEG has high flexibility because its skeleton structure is simple.
- a heavy hydrated layer is formed on the surface layer of the particles by modifying the drug particles and carriers with PEG. It is known that this hydrated layer suppresses the interaction with serum proteins and cells, and as a result, the blood (internal) residence time of the drug is greatly extended (stealthization).
- Non-Patent Document 2 a technique for imparting stealth to a protein drug by using polyvinylpyrrolidone (PVP) as a modifier as a polymer alternative to PEG has been reported (Non-Patent Document 2).
- PVP polyvinylpyrrolidone
- the present inventors have been developing amphipathic compounds having a hydrophilic part and a hydrophobic part in the molecule, mainly on the premise of application to long-term blood-retaining liposomes as drug carriers. Then, in the study at that time, the present inventors have found that PVP exhibits high adsorptivity to plastics such as polypropylene (PP).
- polypropylene (PP) is widely used as a constituent material for a syringe of a syringe.
- a polymer-modified liposome when used as a drug carrier to form an injection solution or a prefilled syringe, or when a polymer-modified protein is used as an active ingredient to form an injection solution or a prefilled syringe.
- the liposome containing the active ingredient is adsorbed on the inner wall of the syringe via the PVP, there is a possibility that a part of the active ingredient contained in the liposome may remain in the syringe without being administered. is there.
- conventionally known PEG-modified liposomes have a problem that the efficiency of uptake into cells is lowered.
- the present invention is a means capable of reducing the adsorptivity to plastics while suppressing a decrease in intracellular uptake efficiency in an amphipathic compound that can be applied to long-term blood-retaining liposomes as a drug carrier.
- the purpose is to provide.
- the monomer (a) having two or more hydroxyl groups in the molecule and having 2 to 10 carbon atoms constituting the side chain among the carbon atoms of the constituent unit is provided.
- the adsorptivity to plastics is reduced while suppressing a decrease in intracellular uptake efficiency. Is possible.
- FIG. 1 compares the particle size of liposomes modified with the amphipathic compound (polymer) (2 w / v% or 4 w / v% PBS solution) prepared in Production Example 4 with that of unmodified liposomes. It is a graph shown by.
- FIG. 2 shows mouse-derived fibroblasts (L929 cells) cultured in the presence of 2 w / v% PBS solution of each amphipathic compound (polymer) prepared in Production Examples 1 to 7 and Comparative Production Example 1. It is a graph which shows the cell viability.
- FIG. 1 compares the particle size of liposomes modified with the amphipathic compound (polymer) (2 w / v% or 4 w / v% PBS solution) prepared in Production Example 4 with that of unmodified liposomes. It is a graph shown by.
- FIG. 2 shows mouse-derived fibroblasts (L929 cells) cultured in the presence of 2 w / v% PBS solution of
- FIG. 3 shows mouse-derived fibers cultured in the presence of liposomes modified with 2 w / v% PBS solutions of the amphipathic compounds (polymers) prepared in Production Examples 1 to 7 and Comparative Production Examples 1. It is a graph which shows the cell viability of a blast cell (L929 cell) in comparison with an unmodified liposome.
- FIG. 4 shows the measurement results of the amount of uptake of the fluorescent substance-encapsulated liposomes modified with the 2 w / v% PBS solution of the amphipathic compound (polymer) prepared in Production Example 4 into HepG2 cells. It is a graph which shows in comparison with the modified liposome and the PEG modified liposome.
- One embodiment of the present invention is a structural unit derived from a monomer (a) having two or more hydroxyl groups in a molecule and having 2 to 10 carbon atoms constituting a side chain among the carbon atoms of the structural unit. It is an amphoteric compound having a moiety (I) containing (A) and a hydrocarbon group having 8 or more carbon atoms.
- the site (I) of the amphipathic compound having such a structure has lower adsorptivity to plastics such as PP as compared with PVP. Therefore, the compound can be applied to long-term blood-retaining liposomes and the like as a drug carrier, but can reduce the adsorptivity to plastics. As a result, for example, it is possible to reduce the possibility that the active ingredient contained therein using the liposome modified with the compound as a drug carrier remains in the syringe. In addition, it is possible to significantly suppress a decrease in intracellular uptake efficiency as seen in PEG-modified liposomes.
- amphipathic compound according to the present invention can exhibit excellent performance when used in the above-mentioned applications, for example, has not been completely clarified, but a mechanism such as hydrophobic adsorption has been presumed. ing. It should be noted that this mechanism is presumed, and the present invention is not limited to this mechanism.
- X to Y indicating a range means “X or more and Y or less”, and "weight” and “mass” are treated as synonyms.
- (meth) acrylate means acrylate or methacrylate
- (meth) acrylic means acrylic or methacrylic
- acrylate and methacrylate may be used alone. It may be used together.
- the operation and physical properties are measured under the conditions of room temperature (20 to 25 ° C.) / relative humidity of 40 to 50%.
- the amphipathic compound according to this embodiment has a site (I) containing a structural unit (A) having a predetermined structure and a hydrocarbon group having 8 or more carbon atoms.
- site (I) containing a structural unit (A) having a predetermined structure and a hydrocarbon group having 8 or more carbon atoms.
- the amphipathic compound according to the present invention first has two or more hydroxyl groups in the molecule, and the number of carbon atoms constituting the side chain among the carbon atoms of the constituent unit is 2 to 10 (a).
- ) Contains a site (I) containing the building block (A).
- the site (I) is derived from the monomer (a) having two or more hydroxyl groups in the molecule and having 2 to 10 carbon atoms constituting the side chain among the carbon atoms of the constituent unit. It is composed of a polymer having the structural unit (A) of.
- structural unit (Q) derived from monomer (P) (P represents an arbitrary appropriate code, and the notation of (P) may not be provided) is typically used. Is a unit (Q) in which one of the polymerizable unsaturated double bond bonds of the "monomer (P)” (or simply “monomer”) is opened by polymerization and constitutes at least a part of the polymer. (Q represents an arbitrary appropriate code, and the notation of (Q) may not be provided).
- the "structural unit derived from the monomer (P)” is a structural unit formed by polymerizing the monomer (P) (or simply the "monomer") as described above (specific examples shown below).
- the structural unit formed by polymerizing the hydroxyl group-protected monomer (a) may be deprotected to form the structural unit (A).
- the monomer (a) having two or more hydroxyl groups in the molecule and having 2 to 10 carbon atoms constituting the side chain among the carbon atoms of the constituent unit is preferably a vinyl monomer.
- (Meta) acrylic monomer is more preferable.
- the monomer (a) may be a monofunctional monomer or a polyfunctional monomer, but preferably contains a monofunctional monomer, and more preferably a monofunctional monofunctional monomer. It consists of a dimer.
- glycerin mono (meth) acrylate also known as 2,3-dihydroxypropyl (meth) acrylate
- 1,2-dihydroxyethyl (meth) (Meta) such as acrylate, 2,2-dihydroxyethyl (meth) acrylate, dihydroxybutyl (meth) acrylate, trimethylolpropane mono (meth) acrylate, pentaerythritol mono (meth) acrylate, dipentaerythritol mono (meth) acrylate, etc.
- Acrylate is preferably used.
- glycerin monoacrylate (GLMA) or glycerin monomethacrylate (GLMMA) is preferable because of its easy industrial availability and high reactivity.
- GLMA glycerin monoacrylate
- GLMMA glycerin monomethacrylate
- the number of carbon atoms constituting the side chain among the carbon atoms of the structural unit derived from the monomer (a) is 2 to 10, but in the present specification, the “side chain” means the structural unit. Refers to the part other than the included main chain.
- the "main chain” means a chain of continuously bonded carbon atoms in a polymer composed of a series of structural units, which has the largest number of carbon atoms.
- the monomer (a) is a methacryl monomer
- the methyl group bonded to the carbon atom constituting the unsaturated double bond in the monomer has both a main chain and a side chain. It shall not be configured.
- the number of carbon atoms constituting the side chain among the carbon atoms of the structural unit derived from the monomer (a) is 2 to 10, but the number of carbon atoms is preferably 3. It is about 8, and more preferably 4 to 6.
- the structural unit (A) preferably includes the structural unit represented by the following chemical formula (1).
- R 1 represents a hydrogen atom or a methyl group, and is preferably a hydrogen atom.
- the proportion of the constituent unit (A) derived from (a) is, for example, 1 to 100% by mass, preferably 20 to 100% by mass, more preferably 50 to 100% by mass, and further preferably 60 to 100% by mass. It is by mass, more preferably 80 to 100% by mass, particularly preferably 90 to 100% by mass, and most preferably 100% by mass. If the ratio of the structural unit (A) is a value within the above range, the effects of the present invention can be exhibited.
- the structural unit (B) is arbitrary radically polymerizable. It may be derived from a monomer (hereinafter, a monomer that becomes a constituent unit (B) by copolymerization is also referred to as “monomer (b)”).
- the ratio of the structural unit (B) to the site (I) is, for example, 99% by mass or less, preferably 80% by mass or less. It is more preferably 50% by mass or less, further preferably 40% by mass or less, still more preferably 20% by mass or less, and particularly preferably 10% by mass or less.
- Examples of the monomer (b) include a hydroxyl group-containing (meth) acrylate, a polyoxyalkylene group-containing monomer, an alkoxyalkyl (meth) acrylate, a vinyl monomer, an alkylene oxide, and an alkoxy other than the monomer (a).
- Examples include polyoxyalkylene glycols, cyclic compounds, amino acids (eg, aspartic acid, glutamic acid) and the like.
- these monomers (b) only one kind may be used alone, or two or more kinds may be used in combination.
- hydroxyl group-containing (meth) acrylate examples include hydroxyalkyl (meth) acrylates in which hydroxyalkyl groups such as 2-hydroxyethyl acrylate and 2-hydroxyethyl methacrylate have 2 to 4 carbon atoms.
- Examples of the polyoxyalkylene group-containing unsaturated monomer include a monomer represented by the following chemical formula (2).
- R 2 , R 3 and R 4 independently represent a hydrogen atom or a methyl group
- R 5 represents an alkylene group having 2 to 18 carbon atoms
- R 6 represents a hydrogen atom or a hydrogen atom or a methyl group.
- X is an alkylene group having 1 to 5 carbon atoms, -CO- group
- R 2 R 4 C CR 3 - group a direct bond when a vinyl group Represented
- m is the average number of added moles of-(R 5 O) -group, and represents a number from 1 to 300.
- (R 5 O) m consists of two or more of R 5 O is 2 or more R 5 O are random, block, alternating of any bound form There may be.
- R 6 is a hydrogen atom or a hydrocarbon group having 1 to 20 carbon atoms.
- R 6 preferably a hydrocarbon group of a hydrogen atom and having 1 to 20 carbon atoms, more preferably a hydrocarbon group having 1 to 10 carbon atoms, more preferably a hydrocarbon group having 1 to 3 carbon atoms, carbon atoms
- One or two hydrocarbon groups are more preferred.
- the hydrocarbon groups an alkyl group or an alkenyl group is preferable, an alkyl group having 1 to 20 carbon atoms is more preferable, an alkyl group having 1 to 10 carbon atoms is more preferable, and an alkyl group having 1 to 3 carbon atoms is even more preferable. preferable.
- the oxyalkylene group represented by -R 5 O- is an oxyalkylene group having 2 to 18 carbon atoms.
- the oxyalkylene group include an oxyethylene group, an oxypropylene group, an oxybutylene group, an oxyisobutylene group, an oxy-1-butene group, an oxy-2-butene group and the like.
- an oxyalkylene group having 2 to 8 carbon atoms is preferable, and an oxyalkylene group having 2 to 4 carbon atoms such as an oxyethylene group, an oxypropylene group and an oxybutylene group is more preferable, and an oxyethylene group. Is even more preferable.
- m is of the formula: average number of moles of the oxyalkylene group represented by -R 5 O-.
- the average number of moles added means the average number of moles of oxyalkylene groups in 1 mole of the unsaturated monomer containing a polyoxyalkylene group.
- the lower limit of m is preferably 2 or more, more preferably 4 or more, and further preferably 8 or more.
- the upper limit of m is preferably 100 or less, more preferably 50 or less.
- polyoxyalkylene group-containing unsaturated monomer examples include unsaturated alcohol polyalkylene glycol adducts, polyalkylene glycol ester monomers, and (alkoxy) polyalkylene glycol monomaleic acid esters.
- the unsaturated alcohol polyalkylene glycol adduct is a compound in which a polyalkylene glycol chain is added to an alcohol having an unsaturated group.
- examples of the unsaturated alcohol polyalkylene glycol adduct include polyethylene glycol monovinyl ether, polyethylene glycol monoallyl ether, polyethylene glycol mono (2-methyl-2-propenyl) ether, polyethylene glycol mono (2-butenyl) ether, and polyethylene glycol.
- Mono (3-methyl-3-butenyl) ether polyethylene glycol mono (3-methyl-2-butenyl) ether, polyethylene glycol mono (2-methyl-3-butenyl) ether, polyethylene glycol mono (2-methyl-2-) Butenyl) ether, polyethylene glycol mono (1,1-dimethyl-2-propenyl) ether, polyethylene glycol glycol mono (3-methyl-3-butenyl) ether, methoxypolyethylene glycol mono (3-methyl-3-butenyl) ether, etc. Can be mentioned.
- the polyalkylene glycol ester-based monomer is a monomer in which an unsaturated group and a polyalkylene glycol chain are bonded via an ester bond.
- polyalkylene glycol ester-based monomer for example, an esterified product of an alkoxypolyalkylene glycol in which 1 to 300 mol of an oxyalkylene group having 2 to 18 carbon atoms is added to an alcohol and (meth) acrylic acid is preferable.
- alkoxypolyalkylene glycols those containing an oxyethylene group as a main component are preferable.
- the alcohol include methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 1-pentanol, 2-pentanol, 3-pentanol, 1-hexanol, 2-hexanol, and the like.
- examples thereof include alcohols, (meth) allyl alcohols, 3-butene-1-ol, 3-methyl-3-buten-1-ol and other unsaturated alcohols having 3 to 30 carbon atoms.
- esterified product examples include methoxypolyethylene glycol mono (meth) acrylate, methoxy (polyethylene glycol polypropylene glycol) mono (meth) acrylate, methoxy (polyethylene glycol polybutylene glycol) mono (meth) acrylate, and methoxy (polyethylene glycol polypropylene glycol).
- Polybutylene glycol) mono (meth) acrylate and the like are preferable.
- alkoxyalkyl (meth) acrylate examples include methoxymethyl (meth) acrylate, methoxyethyl (meth) acrylate, methoxypropyl (meth) acrylate, ethoxymethyl (meth) acrylate, ethoxyethyl (meth) acrylate, and ethoxypropyl (meth) acrylate.
- alkoxyalkyl (meth) acrylate in which an alkoxy group such as a meta) acrylate has 1 to 4 carbon atoms and an alkyl group has 1 to 4 carbon atoms.
- alkoxyalkyl (meth) acrylates may be used alone or in combination of two or more.
- vinyl monomer examples include (meth) acrylic acid, methyl (meth) acrylate, ethyl (meth) acrylate, propyl (meth) acrylate, n-butyl (meth) acrylate, isobutyl (meth) acrylate, and tert-butyl ( Meta) acrylate, 2-ethylhexyl (meth) acrylate, n-lauryl (meth) acrylate, n-stearyl (meth) acrylate, diaminomethyl (meth) acrylate, diaminoethyl (meth) acrylate, dimethylamino (meth) acrylate, diethylamino (Meta) acrylate, glycidyl (meth) acrylate, styrene, aziridines, 2- (meth) acryloyloxymethylphosphorylcholine, 2- (meth) acryloyloxyethyl phosphorylcholine,
- alkylene oxide examples include alkylene oxides having 2 to 4 carbon atoms such as ethylene oxide and propylene oxide.
- alkoxypolyoxyalkylene glycol examples include an alkoxy group having 1 to 4 carbon atoms such as polyethylene glycol, polypropylene glycol, methoxypolyethylene glycol, ethoxypolyethylene glycol, methoxypolypropylene glycol, and ethoxypolyoxyglycol, and an oxy having 1 to 4 carbon atoms.
- cyclic compound examples include lactides such as L-lactide, lactones such as ⁇ -caprolactone, trimethyl carbonate, cyclic amino acids, and morpholine-2,5-dione.
- the polymer constituting the polymer is a block copolymer obtained by bonding polymers of the same type or different types. It may have the structure of.
- the number average molecular weight (Mn) of the polymer is preferably 1000 or more, more preferably 2000 or more, and further preferably 3000 or more from the viewpoint of adsorptivity to the inner wall of the syringe.
- the number average molecular weight (Mn) of the polymer is preferably 90,000 or less, more preferably 30,000 or less, still more preferably 15,000 or less, from the viewpoint of extracorporeal excretion.
- the value of the number average molecular weight (Mn) of the polymer means the value when measured based on the method for measuring Mn of the polymers obtained in Production Examples 1 to 7 in Examples described later. ..
- the molecular weight of the site other than the site (I) (polymer) is subtracted from this measured value.
- the value of Mn of the site (I) (polymer) can be calculated by If an accurate value can be calculated, the value of Mn may be obtained by the same method using only the site (I) (polymer).
- the molecular weight distribution of the polymer is preferably 1 to 1 from the viewpoint of modifying the amphipathic compound (polymer) to liposomes. It is 5, more preferably 1 to 3, still more preferably 1 to 2, still more preferably 1 to 1.5, still more preferably 1 to 1.3.
- the polymer constituting the site (I) can be obtained by polymerizing the monomer (a) and, if necessary, the monomer composition containing the monomer (b).
- the method for polymerizing the above-mentioned monomer composition include a living radical polymerization method represented by a radical polymerization method, an atom transfer radical polymerization method, a reversible addition-opening chain transfer (RAFT) polymerization method, and an ionic polymerization method. Examples thereof include a ring-opening polymerization method, a radical polymerization method, and a polycondensation method, but the present invention is not limited to these examples.
- a solvent may be used when polymerizing the monomer composition.
- the solvent include aromatic solvents such as benzene, toluene and xylene; alcohol solvents such as methanol, ethanol, isopropanol, n-butanol and tert-butanol; halogen atom-containing solvents such as dichloroethane and dichloromethane; diethyl ether, Ether solvents such as propylene glycol methyl ether, dipropylene glycol methyl ether, ethyl cellosolve, butyl cellosolve; ester solvents such as ethyl acetate, butyl acetate, cellosolve acetate; ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone, diacetone alcohol Solvents: Organic solvents such as amide solvents such as dimethylformamide, and water. Each of these solvents may be used alone, or two or more kinds
- a chain transfer agent can be used to adjust the molecular weight of the polymer and to introduce a hydrocarbon group.
- chain transfer agent examples include alkali metal salts of thioacetate such as sodium thioacetate and potassium thioacetate, cysteine, cysteamine, mercaptoethanol, thioglycerol, thioglycolic acid, mercaptopropionic acid, 2-mercaptopropionic acid, and 3-mercapto.
- Hydrophilic thiol-based chain transfer agents such as propionic acid, thioacetic acid, thioannic acid, 2-mercaptoethanesulfonic acid, their sodium salts and potassium salts; primary alcohols such as 2-aminopropan-1-ol, isopropanol and the like.
- Non-thiol chain transfer agents such as (eg, sodium sulfite, sodium hydrogen sulfite, sodium dithionate, sodium metabisulfite, potassium sulfite, potassium hydrogen sulfite, potassium dithionate, potassium metabisulfite, etc.); Butane thiol, octane thiol, decane thiol, dodecane thiol, hexadecane thiol, octadecane thiol, thiocholesterol, cyclohexyl mercaptan, thiophenol, octyl thioglycolate, octyl 2-mercaptopropionate, octyl 3-mercaptopropionate, mercaptopropionic acid 2
- hydrophobic thiol-based chain transfer agents such as -ethylhexyl ester, 2-mercaptoethyl ester of oct
- RAFT reversible additional cleavage chain transfer
- RAFT agents include 4-cyano-4- (phenylcarbonotioilthio) pentanoic acid, 2-cyano-2-propylbenzothioate, 2-cyano-2-propyldodecyltrithiocarbonate, 4-.
- the amount of the chain transfer agent may be appropriately set according to the type of the monomer contained in the monomer composition, the polymerization conditions such as the polymerization temperature, the molecular weight of the target polymer, and the like, and is not particularly limited. However, when a polymer having a number average molecular weight of several thousand to several tens of thousands is obtained, the amount of the chain transfer agent is preferably 0.1 to 20 parts by mass per 100 parts by mass of the monomer, preferably 0.5. It is more preferably to 15 parts by mass.
- a polymerization initiator When polymerizing the monomer composition, a polymerization initiator can be used.
- polymerization initiator examples include azoisobutyronitrile, 2,2'-azobis (4-dimethoxy-2,4-dimethylvaleronitrile), 4,4'-azobis (4-cyanopentanoic acid), 2, 2'-azobis [2-methyl-N- [1,1-bis (hydroxymethyl) -2-hydroxyethyl] propionamide], 2,2'-azobis [N- (2-hydroxyethyl) -2-methoxy Propanamide], 2,2'-azobis (2-methyl-2-propenylpropanamide), 2,2'-bis (2-imidazolin-2-yl) [2,2'-azobispropane] dihydrochloride , 2,2'-azobis (propane-2-carbamomidin) dihydrochloride, 2,2'-azobis [N- (2-carboxyethyl) -2-methylpropion amidine], 2,2'-azobis [2 -[1- (2-Hydroxyethyl) -2-
- Radical polymerization initiator bromomethylbenzene, 1- (bromomethyl) -4-methylbenzene, ethyl 2-bromoisobutyrate, hydroxyethyl 2-bromoisobutyrate, bis [2- (2'-bromoisobutyryloxy) ethyl]
- living radical polymerization initiators such as disulfide, 10-undecenyl 2-bromoisobutyrate, and 4- (1-bromoethyl) benzoic acid. These polymerization initiators may be used alone or in combination of two or more.
- the amount of the polymerization initiator may be appropriately set according to the desired physical properties of the obtained polymer, etc., but usually, the amount of the polymerization initiator is preferably 0.001 to 20 per 100 parts by mass of the monomer. It is by mass, more preferably 0.005 to 10 parts by mass.
- the polymerization conditions for polymerizing the monomer composition may be appropriately set according to the polymerization method, and are not particularly limited.
- the polymerization temperature is preferably room temperature to 200 ° C., more preferably 40 to 140 ° C.
- the atmosphere for polymerizing the monomer composition is preferably an inert gas such as nitrogen gas or argon gas.
- the reaction time may be appropriately set so that the polymerization reaction of the monomers is completed.
- a polymer constituting the site (I) By polymerizing the monomer composition as described above, a polymer constituting the site (I) can be obtained.
- the obtained polymer may have a functional group at its terminal.
- the polymer constituting the site (I) modifies a drug or the like via the functional group, or links it with a predetermined hydrocarbon group described later via the functional group. Can be easily done.
- the polymer constituting the site (I) does not have to have a functional group at its terminal.
- the amphipathic compound according to the present invention has a hydrocarbon group having 8 or more carbon atoms and a site (I) (including a polymer) in the molecule, and constitutes the site (I).
- the functional group may be present at only one end of the polymer or at both ends. Further, the functional group existing at the end of the polymer may be located on the side where the site (I) is bonded to a predetermined hydrocarbon group described later, or is located on the opposite side. May be.
- an anionic functional group, a cationic functional group, a nonionic functional group and an amphoteric functional group are preferable.
- the functional group is preferably a reactive functional group. Suitable reactive functional groups include -SH group, formula: -COMM (M represents hydrogen atom or alkali metal atom), hydroxyl group, allyl group, epoxy group, aldehyde group, -NH 2 group. , CONH-group and the like. Examples of the M include alkali metal atoms such as sodium atom and potassium atom.
- the number of the functional groups is not particularly limited, but is preferably 1 to 6, more preferably 1 to 4, and even more preferably 1 to 2. Is.
- a functional group-containing compound for introducing a functional group into the polymer can be used.
- the functional group-containing compound for introducing a functional group into the terminal of the polymer include alkali metal thioacetate salts such as sodium thioacetate and potassium thioacetate, cysteine, cysteamine, mercaptoethanol, thioglycerol, and thioglycolic acid.
- Examples thereof include a polymerization initiator.
- Each of these functional group-containing compounds may be used alone, or two or more thereof may be used in combination.
- the functional group-containing compounds described above include those corresponding to the above-mentioned chain transfer agents and polymerization initiators, but the functional group-containing compounds corresponding to the chain transfer agents and polymerization initiators are chain transfer agents or polymerization initiators. It may be used for the purpose of only one of the initiator and the functional group-containing compound, or it may be used for both purposes.
- the polymer is prepared by reacting a functional group-containing compound with a halogen atom existing at the terminal of the polymer prepared by using the living polymerization initiator.
- a functional group may be introduced at the end.
- the functional group-containing compound capable of reacting with such a halogen atom to introduce a functional group at the terminal of the polymer include amine compounds such as ethylenediamine and propyldiamine, and dithiols such as ethanedithiol, propanedithiol and hexadecanedithiol.
- the amount of the functional group-containing compound for introducing a functional group into the terminal of the polymer includes the type of monomer (constituent unit) constituting the polymer, polymerization conditions such as polymerization temperature, and the target molecular weight of the polymer. It may be set as appropriate according to the above, and is not particularly limited.
- the amount of the chain transfer agent is preferably 0.1 to 20 parts by mass, and 0.5 to 15 parts by mass, per 100 parts by mass of the monomer. More preferably, it is by mass.
- a method of introducing a functional group into the terminal of the polymer constituting the site (I) for example, (1) A method for obtaining a polymer by polymerizing a monomer composition in the presence of a polymerization initiator into which the functional group has been introduced as a polymerization initiator. (2) A method for obtaining a polymer by polymerizing a monomer composition in the presence of a chain transfer agent into which the functional group has been introduced as a chain transfer agent. (3) Examples thereof include a method of reacting a halogen atom existing at the terminal of the polymer with a functional group-containing compound, but the present invention is not limited to such an example.
- the amphipathic compound according to the present invention has 8 carbon atoms in addition to the above-mentioned "site (I) containing a structural unit (A) derived from a monomer (a) having two or more hydroxyl groups in the molecule". It is characterized in that it also has the above hydrocarbon groups.
- the specific configuration of the hydrocarbon group is not particularly limited.
- the hydrocarbon group is preferably a group contained in an organic compound having the ability to form an aggregate of molecules by hydrophobic interaction in an aqueous solution.
- organic compounds include hydrocarbons, hydrophobic polymers, lipids, and other organic molecules.
- hydrocarbon examples include an aliphatic hydrocarbon having 8 to 50 carbon atoms and an aromatic hydrocarbon having 8 to 50 carbon atoms. That is, in a preferred embodiment of the present invention, the hydrocarbon group has 8 to 50 carbon atoms, more preferably 8 to 40, still more preferably 8 to 30, and particularly preferably 8 to 20. ..
- Examples of aliphatic hydrocarbons having 8 to 50 carbon atoms include linear alkanes such as octane, nonan, decane, undecane, dodecane, tridecane, tetradecane, pentadecane, hexadecane, heptadecane, octadecane, nonadecane, and icosan. Examples thereof include these branched alkanes and these cyclic alkanes, and linear alkanes are preferable.
- aromatic hydrocarbons having 8 to 50 carbon atoms examples include 2-phenylethane, 1,3,5-trimethylbenzene, naphthalene, anthracene, fluorescein, and their positional isomers.
- hydrophobic polymer examples include a polymer obtained by polymerizing a vinyl monomer having a hydrocarbon group having 8 or more carbon atoms in a side chain as a main component among vinyl monomers that can be a constituent unit of the above-mentioned site (I).
- Lipid means an organic compound having a long-chain fatty acid or a hydrocarbon chain, which is sparingly soluble in water and easily soluble in an organic solvent.
- “Lipids” can be further broadly classified into phospholipids, glycolipids, sphingolipids, sterols, neutral lipids, saturated or unsaturated fatty acids and the like.
- Phospholipids are roughly classified into glycerophospholipids and sphingolipids.
- Typical examples of glycerophospholipids include phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylglycerol (PG), phosphatidylethanolamine (PE), and phosphatidylate (PA).
- a typical sphingolipid is sphingomyelin.
- Specific examples of phospholipids include the lipids described in (a) to (i) below.
- A Phosphatidylcholine Dipalmitoylphosphatidylcholine (DPPC), dipalmitoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DLPC), as specific examples of phosphatidylcholine.
- DPPC dipalmitoylphosphatidylcholine
- DSPC dipalmitoylphosphatidylcholine
- DMPC dipalmitoylphosphatidylcholine
- DOPC dipalmitoylphosphatidylcholine
- DLPC dipalmitoylphosphatidylcholine
- DDPC dipalmitoylphosphatidylcholine
- DOPC dioctanoylphosphatidylcholine
- DHPC dihexanoylphosphatidylcholine
- DBPC dibutyrylphosphatidylcholine
- DEPC dialmitoylphosphatidylcholine
- DEPC dialmitoylphosphatidylcholine
- diheptanoylphosphatidylcholine dicaproylphosphatidylcholine, diheptadecanoylphosphatidylcholine, dibehenoylphosphatidylcholine, eleostearoylphosphatidylcholine, hydrided egg phosphatidylcholine (HEPC), hydrided soyphosphatidylcholine (HSPC), 1-palmitoyl- 2-Arachidnoylphosphatidylcholine
- phosphatidylserines include distearoyl phosphatidylserine (DSPS), dimyristyl phosphatidylserine (DMPS), dilauroyl phosphatidylserine (DLPS), dipalmitoyl phosphatidylserine (DPPS), and diore oil.
- DSPS distearoyl phosphatidylserine
- DMPS dimyristyl phosphatidylserine
- DLPS dimyristyl phosphatidylserine
- DLPS dilauroyl phosphatidylserine
- DPPS dipalmitoyl phosphatidylserine
- diore oil examples include phosphatidylserine (DOPS), lysophosphatidylserine, eleostearoyl phosphatidylserine and 1,2-di- (9-cis-oct
- phosphatidylinositols include dipalmitoylphosphatidylinositol (DPPI), distearoylphosphatidylinositol (DSPI), and dilauroylphosphatidylinositol (DLPI).
- DPPI dipalmitoylphosphatidylinositol
- DSPI distearoylphosphatidylinositol
- DLPI dilauroylphosphatidylinositol
- phosphatidylglycerols include dipalmitylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), dioleoil phosphatidylglycerol (DOPG), dilauroylphosphatidylglycerol (DLPG), and dimyristoyl.
- DPPG dipalmitylphosphatidylglycerol
- DSPG distearoylphosphatidylglycerol
- DOPG dioleoil phosphatidylglycerol
- DLPG dimyristoyl
- DMPG phosphatidylglycerol
- HSPG hydrided soyphosphatidylglycerol
- HEPG hydrided egg phosphatidylglycerol
- cardiolipin diphosphatidylglycerol
- Phosphatidylethanolamine Classes Specific examples of phosphatidylethanolamine (cephalin) are dipalmitylphosphatidylethanolamine (DPPE), distearoylphosphatidylethanolamine (DSPE), dioreoil phosphatidylethanolamine (DOPE) , Dilauroylphosphatidylethanolamine (DLPE), dimyristylphosphatidylethanolamine (DMPE), didecanoylphosphatidylethanolamine (DDPE), N-glutalylphosphatidylethanolamine (NGPE), lysophosphatidylethanolamine, N- (7-) Nitro-2,1,3-benzoxydiasol-4-yl) -1,2-dioreoil-sn-phosphatidylethanolamine, eleostearoylphosphatidylethanolamine, N-succinyldioreoil phosphatidylethanolamine and 1-hex
- distearoyl N- (3-maleimide-1-oxopropyl) -L- ⁇ -phosphatidylethanolamine which is a derivative of distearoylphosphatidylethanolamine (DSPE) having a maleimide group
- DSPE distearoylphosphatidylethanolamine
- COATSOME registered trademark
- FE-8080MA3 manufactured by Co., Ltd. is used as a raw material for lipids.
- phosphatidylethanolamines (and other lipid derivatives) having a functional group such as a maleimide group or a succinimide group for linking with the site (I) together with a hydrocarbon group having 8 or more carbon atoms. Can also be used in the same way.
- phosphatidic acids include dipalmitoyl phosphatidic acid (DPPA), distearoyl phosphatidic acid (DSPA), dimyristyl phosphatidic acid (DMPA) and dioleyl phosphatidic acid (DOPA).
- DPPA dipalmitoyl phosphatidic acid
- DSPA distearoyl phosphatidic acid
- DMPA dimyristyl phosphatidic acid
- DOPA dioleyl phosphatidic acid
- Sphingolipids include sphingomyelin, dipalmitoyl sphingomyelin, distearoyl sphingomyelin, ceramide silitin, ceramide phosphorylethanolamine, and ceramide phosphorylglycerol.
- glycolipids are roughly classified into glyceroglycolipids and glycosphingolipids.
- glycolipids include the lipids described in (a) to (c) below.
- (A) Glyceroglycolipid As specific examples of glyceroglycolipid, diglyceride diglyceride, glycosyl diglyceride, digalactosyl diglyceride, galactosyl diglyceride, sulfoxyribosyl diglyceride, (1,3) -D-mannosyl (1,3) diglyceride, Digalactosyl glyceride, digalactosyl dilauroyl glyceride, digalactosyl dimyristyl glyceride, digalactosyl dipalmitoyl glyceride, digalactosyl distearoyl glyceride, galactosyl glyceride, galactosyl dilauroyl glyceride, galactosyl dimyristyl glyceride, galactosyl dipalmitoyl glyceride And diga
- Sphingo glycolipids include ceramide (cerebroside), galactosylceramide, lactosylceramide, digalactosylceramide, ganglioside GM1, ganglioside GM2, ganglioside GM3, sulfatide, ceramide oligohexoside and globoside. Can be mentioned.
- glycolipids examples include ceramide oligohexoside, palmityl glycoside, stearyl glucoside, myristyl glucoside, alkyl glycoside, aminophenyl glycoside, cholesteryl maltoside, cholesteryl glucoside, and 3-cholesteryl-6'.
- ceramide oligohexoside palmityl glycoside
- stearyl glucoside myristyl glucoside
- alkyl glycoside aminophenyl glycoside
- cholesteryl maltoside cholesteryl glucoside
- 3-cholesteryl-6' 3-cholesteryl-6'.
- -(Glycosidic thio) hexyl ether glycolipids and glucamides can be mentioned.
- sterols include, for example, cholesterol succinic acid, dihydrocholesterol, lanosterol, dihydrolanosterol, desmosterol, stigmasterol, citosterol, campesterol, brush casterol, timosterol, ergosterol, campersterol, fucosterol, 22-ketosterol, 20-hydroxysterol, 7-hydroxycholesterol, 19-hydroxycholesterol, 22-hydroxycholesterol, 25-hydroxycholesterol, 7-dehydrocholesterol, 5 ⁇ -cholest-7-en-3 ⁇ -ol, epicholesterol, Dehydroergosterol, cholesterol sulfate, cholesterol hemicohactate, cholesterol phthalate, cholesterol phosphate, cholesterol valerate, cholesterol hemisuccinate, 3 ⁇ N- (N', N'-dimethylaminoethane) -carbamoyl cholesterol, cholesterol acetate, cholesteryl oleate
- Neutral lipids include, for example, diglycerides (eg diolein, dipalmitole) and mixed capriline-caprindiglycerides, triacylglycerols (triolein, tripalmitole, trimyristoline, trilaurin, tricaprin, tricapriline, tricaproin, etc.), squalene, Examples include tocopherol and cholesterol.
- diglycerides eg diolein, dipalmitole
- mixed capriline-caprindiglycerides eg diolein, dipalmitole
- triacylglycerols triolein, tripalmitole, trimyristoline, trilaurin, tricaprin, tricapriline, tricaproin, etc.
- squalene examples include tocopherol and cholesterol.
- saturated fatty acids and unsaturated fatty acids include caprylic acid, pelarganoic acid, capric acid, undecyleneic acid, lauric acid, tridecilenic acid, myristic acid, pentadecilenic acid, palmitic acid, margaric acid, stearic acid, nonadesilenic acid, and arachidic acid.
- saturated or unsaturated fatty acids having 5 to 30 carbon atoms such as dodecenoic acid, tetradecenoic acid, oleic acid, linoleic acid, linoleic acid, aicosenoic acid, erucic acid and docosapentaenoic acid.
- the amphoteric compound according to the present invention has 8 or more carbon atoms. It can be used as a source of hydrocarbon groups in the above.
- fat-soluble vitamins such as vitamin A (retinol), vitamin D (calciferol), vitamin E (tocopherol), vitamin K and derivatives thereof can be mentioned.
- an organic molecule for example, dialkylglycerol
- composed of one or more long-chain alkyl chains (8 or more carbon atoms) and a carbon molecule such as fullerene C60 are also hydrocarbon groups having 8 or more carbon atoms.
- the hydrocarbon group having 8 or more carbon atoms contains the structural unit (A) directly or via a divalent bonding group.
- Lipids eg, phospholipids
- a hydrocarbon group having 8 or more carbon atoms may also have a functional group at the terminal thereof, similarly to the polymer constituting the site (I).
- a hydrocarbon group having 8 or more carbon atoms has a functional group at the terminal thereof, it is possible to modify a drug or the like via the functional group.
- a hydrocarbon group having 8 or more carbon atoms does not have to have a functional group at its terminal.
- the functional group may be present only at one end of the hydrocarbon group having 8 or more carbon atoms, and at both ends. It may exist.
- the functional group existing at the terminal of the hydrocarbon group having 8 or more carbon atoms may be located on the side where the hydrocarbon group having 8 or more carbon atoms is bonded to the site (I). It may be located on the opposite side of.
- the molecular weight of the hydrocarbon group having 8 or more carbon atoms is preferably 5000 or less, preferably 2000 or less, and more preferably 1000 or less from the viewpoint of extracorporeal excretion. It is preferably 100 or more, and more preferably 150 or more.
- the ratio of the molecular weight of the "hydrocarbon group having 8 or more carbon atoms" to the molecular weight of the amphipathic compound is preferably 0.2 to 20%, more preferably 0.5 to 15%. , More preferably 1 to 10%.
- the molecular weight of the lipid is preferably 2000 or less, more preferably 2000 or less. It is 1000 or less.
- the ratio of the molecular weight of the lipid to the molecular weight of the amphipathic compound is preferably 2. It is ⁇ 50%, more preferably 5 ⁇ 35%, still more preferably 10 ⁇ 20%.
- the divalent bonding group is a group that bonds a site (I) and a hydrocarbon group having 8 or more carbon atoms, and its structure is not particularly limited and may be a part of the structure of the site (I). It may be included.
- Ra is a hydrogen atom or a hydrocarbon group having 1 to 30 carbon atoms.
- the R b is a hydrocarbon group having 1 to 30 carbon atoms.
- the residue obtained by removing one hydrogen atom and one hydrocarbon group having 8 or more carbon atoms from the lipid (including a modified product of the lipid) is also one of the preferable forms of the divalent bonding group. is there.
- the divalent bonding group preferably has a molecular weight of 5000 or less, more preferably 2000 or less, and even more preferably 1000 or less.
- a monomer composition is used in the presence of a chain transfer agent and / or a polymerization initiator.
- the chain transfer agent and / or the polymerization initiator has a structure capable of forming a site containing a hydrocarbon group having 8 or more carbon atoms. Examples thereof include a method using a chain transfer agent or a polymerization initiator contained therein.
- a hydrocarbon group having 8 or more carbon atoms can be obtained.
- An amphoteric compound formed by binding to the site (I) via a thioether bond (—S—) can be obtained (see Production Examples 1 to 6 described later).
- the monomer composition is polymerized in the presence of a chain transfer agent.
- RAFT polymerization is carried out using a reversible addition-cleaving chain transfer (RAFT) agent as the chain transfer agent, thereby forming the polymer constituting the site (I).
- RAFT reversible addition-cleaving chain transfer
- a thiol group (-SH group) is introduced at the end of.
- a compound having a functional group capable of reacting with a thiol group (-SH group) is reacted with the thiol group (-SH group) together with a hydrocarbon group having 8 or more carbon atoms.
- a hydrocarbon group having 8 or more carbon atoms and the site (I) can be linked via the thioether bond (—S—) (see Production Example 7 described later).
- This technique is particularly useful when hydrocarbon groups with 8 or more carbon atoms are present in amphipathic compounds as part of lipids or other organic molecules.
- the polymer constituting the site (I) or the polymer in which a hydrocarbon group having 8 or more carbon atoms is present in the compound as a part of the polymer It may have a crosslinked structure.
- the method for cross-linking the polymer include a chemical cross-linking method and a physical cross-linking method.
- Chemical cross-linking methods include, for example, epoxy compounds, oxidized starch, glutaaldehyde, formaldehyde, dimethyl suberiminoate, carbodiimide, succinimidyl compounds, diisosianate compounds, acyl azide, reuterin, tris (hydroxymethyl) phosphine, copper ascorbate, glucose Methods such as cross-linking the polymer with a chemical cross-linking agent such as lysine or photooxidant, heat dehydration treatment, irradiation with ultraviolet rays, irradiation with electron beams, irradiation with gamma rays, etc. Can be mentioned.
- the physical cross-linking method includes, for example, a method of cross-linking the polymer with a salt, a method of cross-linking the polymer by electrostatic interaction, a method of cross-linking the polymer by hydrogen bonding, and a method of cross-linking the polymer by hydrophobic interaction.
- the number average molecular weight (Mn) of the amphipathic compound according to the present invention is preferably 1000 or more, more preferably 2000 or more, preferably 100,000 or less, and further preferably 50,000 or less.
- a medical resin composition containing an amphipathic compound according to the present invention containing an amphipathic compound according to the present invention.
- This medical resin composition may consist of an amphipathic compound according to the present invention, or may further contain other components.
- Other ingredients include, for example, water, physiological saline, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium carboxymethyl cellulose salt, sodium polyacrylate, sodium alginate, water soluble.
- Dextran carboxymethyl starch sodium, pectin, methyl cellulose, ethyl cellulose, xanthan gum, gum arabic, casein, gelatin, agar, diglycerin, propylene glycol, polyethylene glycol, vaseline, paraffin, stearyl alcohol, stearic acid, human serum albumin, mannitol, sorbitol , Lactose, phosphate buffered physiological saline, biodegradable polymers, serum-free media, surfactants allowed as pharmaceutical additives, physiological pH buffers allowed in vivo, and the like. Each of these additives may be used alone, or two or more thereof may be used in combination.
- the amphipathic compound or medical resin composition according to the present invention can be suitably used as a pharmaceutical additive.
- the pharmaceutical additive include a carrier for holding a pharmaceutical product and the like.
- the functional part (I) constituting the amphoteric compound or a hydrocarbon group having 8 or more carbon atoms has.
- a method of coating with an amphoteric compound or a medical resin composition, a method of encapsulating a mixture of a lipid and an amphoteric compound or a medical resin composition, and encapsulating a drug or the like inside the obtained particles, a pharmaceutical By coating particles encapsulating such as in liposomes with an amphoteric compound or a medical resin composition, a method of encapsulating the particles inside the outer skin of the amphipathic compound or the medical resin composition, a medicine, etc.
- a method of encapsulating the particles inside the outer skin of the amphoteric compound or the medical resin composition, a drug, etc a method of encapsulating the particles inside the outer skin of the amphoteric compound or the medical resin composition, a drug, etc.
- the present invention is not limited to such examples.
- the liposome was prepared by, for example, dissolving the lipid in a solvent such as tert-butyl alcohol and then freeze-drying, or adding a solution in which the drug was dissolved to the lipid to swell the lipid and disperse it with ultrasonic waves. Later, it can be prepared by a method of adding polyethylene glycol-phosphatidylethanolamine or the like to the obtained dispersion.
- the liposome is preferably cationized with a cationizing agent.
- a cationizing agent conventionally known ones can be appropriately selected and used.
- Liposomes can be obtained, for example, by dissolving hydrided soybean lecithin, cholesterol, 3,5-dipentadecyloxybenzamidine hydrochloride or the like in a solvent such as tert-butyl alcohol and freezing the obtained lipid mixed solution. Can be done.
- the lipids that make up liposomes are stable in vivo.
- those exemplified above as a source of hydrocarbon groups having 8 or more carbon atoms can be similarly used.
- liposomes were mentioned in the above example, for example, emulsions, nanoparticles, microparticles, polymer compounds, etc. can be used instead of liposomes.
- a biologically or pharmacologically active medicine can be used.
- Pharmaceuticals include, for example, antitumor agents, anticancer agents, antibiotics, antiviral agents, anticancer effect enhancers, immunopotentiators, immunomodulators, immunorecovery agents, radiation sensitizers, radiation protective agents, antihistamines, anti-inflammatory agents.
- Mammals such as humans, monkeys, mice, and livestock are examples of the subject to which the drug is administered, but the present invention is not limited to such examples.
- the drug When the drug is administered by injection, the drug can be injected into the body by, for example, intravenous injection such as instillation, intramuscular injection, intraperitoneal injection, subcutaneous injection, intradermal injection, intratumoral injection, or the like.
- intravenous injection such as instillation, intramuscular injection, intraperitoneal injection, subcutaneous injection, intradermal injection, intratumoral injection, or the like.
- the hydrophilic moiety of the amphipathic compound according to the present invention has lower adsorptivity to plastics such as PP as compared with PVP. Therefore, the compound can be applied to long-term blood-retaining liposomes and the like as a drug carrier, but can reduce the adsorptivity to plastics. As a result, for example, it is possible to reduce the possibility that the active ingredient contained in the liposome modified with the compound remains in the syringe.
- amphipathic compound or medical resin composition according to the present invention is a pharmaceutical additive used as a carrier for holding a pharmaceutical or the like in the form of a liposome or the like.
- the drug additive is preferably added to the drug administered in the form of an injection.
- the amount of the drug to be retained in the amphipathic compound or the medical resin composition according to the present invention varies depending on the subject to which the drug is administered, the type of the drug, and the like, and therefore cannot be unconditionally determined.
- the amount of the drug is preferably about 1 ⁇ g to 50 g per 100 g of the solid content contained in the amphipathic compound or the medical resin composition according to the present invention.
- amphipathic compound (polymer)
- An amphipathic compound having a polymer form was produced by the following method.
- the obtained reaction solution was added dropwise to diethyl ether for purification to obtain a polyglycerin monoacrylate containing an alkyl group (n-dodecyl group) at the terminal.
- the number average molecular weight of the obtained amphipathic compound (polymer) was 2200.
- the molecular weight of the hydrocarbon group (n-dodecyl group) having 8 or more carbon atoms is 169.3.
- the obtained reaction solution was added dropwise to diethyl ether for purification to obtain a polyglycerin monoacrylate containing an alkyl group (n-dodecyl group) at the terminal.
- the number average molecular weight of the obtained amphipathic compound (polymer) was 10900.
- the molecular weight of the site (n-dodecyl group) containing a hydrocarbon group having 8 or more carbon atoms is 169.3.
- the precipitated portion of the obtained reaction solution was dissolved in 1.0 g of ethanol and further added dropwise to diethyl ether for purification to obtain polyglycerin monomethacrylate containing an alkyl group (n-octadecyl group) at the terminal.
- the number average molecular weight of the obtained amphipathic compound (polymer) was 14,000. Of these, the molecular weight of the hydrocarbon group (n-octadecyl group) having 8 or more carbon atoms is 253.5.
- the lipid suspension was transferred to a microtest tube, 4 times the amount of PBS was added, and then centrifuged at 15000 ⁇ G for 20 minutes to precipitate the formed liposomes. After centrifugation, discard the supernatant, add 1 mL of new PBS, resuspend, and sizing with an extruder (pore size 0.1 ⁇ m) warmed to 65 ° C., and the lipid equivalent is 12.9 mg / mL. A liposome suspension was obtained. The concentration of the liposome suspension was measured using Lab Assay (trademark) phospholipid (Fujifilm Wako Pure Chemical Industries, Ltd.), and the measurement protocol was based on the attached manual.
- Polymer solutions having different concentrations were prepared by dissolving in PBS to a concentration of v%.
- Each of the polymer solutions and the liposome suspension prepared above were mixed in equal volumes and allowed to stand at 10 ° C. for 60 minutes to modify the amphipathic compound into liposomes.
- the particle size of the liposome was 160.6 ⁇ 5.2 nm in the control group.
- the particle sizes of the liposomes modified with the 2w / v% and 4w / v% polymer solutions were 174.8 ⁇ 6.5 nm and 174.6 ⁇ 5.5 nm, respectively, and the amphipathic compounds were used. It was confirmed that the particle size increased due to the modification used.
- L929 cells cultured in a 100 mm cell culture dish to a state of 70% confluence were treated with 0.25 w / v% trypsin / 50 mM EDTA solution, and the above-mentioned serum-added DMEM medium was added to stop the trypsin reaction, and L929.
- a cell suspension was obtained.
- the number of cells in the L929 cell suspension was measured using a 0.4 w / v% trypan blue solution (Fujifilm Wako Pure Chemical Industries, Ltd.).
- the cell suspension was seeded on a 96-well plate (Thermo Fisher Science) so that the number of cells per well was 2.5 ⁇ 10 3 cells, and cultured at 37 ° C. under 5% CO 2 conditions for 24 hours.
- the measurement protocol conformed to the manual attached to the kit.
- the survival rate of L929 cells was calculated from the following formula based on the measured values of the wells tested by adding PBS instead of the polymer solution and the measured values of the wells to which each sample was added.
- L929 cells cultured in a 100 mm cell culture dish to a state of 70% confluence were treated with 0.25 w / v% trypsin / 50 mM EDTA solution, and the above-mentioned serum-added DMEM medium was added to stop the trypsin reaction, and L929.
- a cell suspension was obtained.
- the number of cells in the L929 cell suspension was measured using a 0.4 w / v% trypan blue solution (Fujifilm Wako Pure Chemical Industries, Ltd.).
- the cell suspension was seeded on a 96-well plate (Thermo Fisher Science) so that the number of cells per well was 2.5 ⁇ 10 3 cells, and cultured at 37 ° C. under 5% CO 2 conditions for 24 hours.
- the absorbance was measured with a plate reader SH-9000 (Corona Electric Co., Ltd.). The measurement protocol conformed to the manual attached to the kit.
- the viability of L929 cells was calculated from the following formula based on the measured values of the wells tested by adding PBS instead of the modified liposome suspension and the measured values of the wells to which each sample was added.
- the lipid suspension was transferred to a microtest tube, 4 times the amount of PBS was added, and then centrifuged at 15000 ⁇ G for 20 minutes to precipitate the formed liposomes. After centrifugation, discard the supernatant, add 1 mL of new PBS, resuspend, and sizing with an extruder (pore size 0.1 ⁇ m) warmed to 65 ° C., and the lipid equivalent is 13.7 mg / mL. A liposome suspension was obtained.
- Labassay TM phospholipid (Fujifilm Wako Pure Chemical Industries, Ltd.) was used to measure the concentration of the liposome suspension, and the measurement protocol was based on the attached manual.
- HePG2 cells cultured in a 100 mm cell culture dish to a 70% confluent state were treated with a 0.25 w / v% trypsin / 50 mM EDTA solution, and the above-mentioned serum-added MEM medium was added to stop the trypsin reaction, and HepG2.
- a cell suspension was obtained.
- the number of cells in the HepG2 cell suspension was measured using a 0.4 w / v% trypan blue solution (Fujifilm Wako Pure Chemical Industries, Ltd.).
- the cell suspension was seeded on a 24-well plate (Thermo Fisher Science) so that the number of cells per well was 4 ⁇ 10 4 cells, and cultured at 37 ° C. under 5% CO 2 conditions for 48 hours.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本形態に係る両親媒性化合物は、所定の構造を有する構成単位(A)を含む部位(I)と、炭素原子数8以上の炭化水素基とを有するものである。以下、これらの構成要素について、詳細に説明する。
本発明に係る両親媒性化合物は、まず、分子内に水酸基を2個以上有し、構成単位の炭素原子のうち側鎖を構成する炭素原子の数が2~10である単量体(a)由来の構成単位(A)を含む部位(I)を有する。好ましい実施形態において、部位(I)は分子内に水酸基を2個以上有し、構成単位の炭素原子のうち側鎖を構成する炭素原子の数が2~10である単量体(a)由来の構成単位(A)を有する重合体からなる。ここで、本明細書において「単量体(P)由来の構造単位(Q)」(Pは任意の適切な符号を表し、(P)の表記はない場合もある)とは、代表的には、「単量体(P)」(または単に「単量体」)が有する重合性不飽和二重結合の結合の一つが重合によって開き、重合体の少なくとも一部を構成する単位(Q)(Qは任意の適切な符号を表し、(Q)の表記はない場合もある)となったものを意味する。上記「単量体(P)由来の構造単位」には、上記のように単量体(P)(または単に「単量体」)が重合して形成される構造単位(下記に示す具体例では一般式(Q)で表される構造単位)と同じ構造であれば、別の製法によって形成された構造単位であってもよい。例えば、水酸基が保護された単量体(a)を重合して形成された構造単位に対して脱保護処理を施して構成単位(A)を形成してもよい。例えば、(2-メチル-2-エチル-1,3-ジオキソラン-4-イル)メチル(メタ)アクリレートまたはグリシジルエーテル(メタ)アクリレートを重合後、加水分解してグリセリン(メタ)アクリレート由来の構造単位を形成してもよい。
(1)重合開始剤として前記官能基が導入された重合開始剤の存在下で単量体組成物を重合して重合体を得る方法、
(2)連鎖移動剤として前記官能基が導入された連鎖移動剤の存在下で単量体組成物を重合して重合体を得る方法、
(3)重合体の末端に存在するハロゲン原子と官能基含有化合物とを反応させる方法
などが挙げられるが、本発明は、かかる例示のみに限定されるものではない。
本発明に係る両親媒性化合物は、上述した「分子内に水酸基を2個以上有する単量体(a)由来の構成単位(A)を含む部位(I)」に加えて、炭素原子数8以上の炭化水素基をも有する点に特徴がある。当該炭化水素基の具体的な構成は特に制限されない。
ホスファチジルコリン類の具体例としては、ジパルミトイルホスファチジルコリン(DPPC)、ジステアロイルホスファチジルコリン(DSPC)、ジミリストリルホスファチジルコリン(DMPC)、ジオレオイルホスファチジルコリン(DOPC)、ジラウロイルホスファチジルコリン(DLPC)、ジデカノイルホスファチジルコリン(DDPC)、ジオクタノイルホスファチジルコリン(DOPC)、ジヘキサノイルホスファチジルコリン(DHPC)、ジブチリルホスファチジルコリン(DBPC)、ジエライドイルホスファチジルコリン、ジリノレオイルホスファチジルコリン、ジアラキドノイルホスファチジルコリン、ジイコセノイルホスファチジルコリン(DEPC)、ジヘプタノイルホスファチジルコリン、ジカプロイルホスファチジルコリン、ジヘプタデカノイルホスファチジルコリン、ジベヘノイルホスファチジルコリン、エレオステアロイルホスファチジルコリン、水素化卵ホスファチジルコリン(HEPC)、水素化大豆ホスファチジルコリン(HSPC)、1-パルミトイル-2-アラキドノイルホスファチジルコリン、1-パルミトイル-2-オレオイルホスファチジルコリン、1-パルミトイル-2-リノレオイルホスファチジルコリン、1-パルミトイル-2-ミリストイルホスファチジルコリン、1-パルミトイル-2-ステアロイルホスファチジルコリン、1-ステアロイル-2-パルミトイルホスファチジルコリン、1,2-ジミリストイルアミド-1,2-デオキシホスファチジルコリン、1-ミリストイル-2-パルミトイルホスファチジルコリン、1-ミリストイル-2-ステアロイルホスファチジルコリン、ジ-0-ヘキサデシルホスファチジルコリン、トランスジエライドイルホスファチジルコリン、ジパルミテライドイル-ホスファチジルコリン、n-オクタデシル-2-メチルホスファチジルコリン、n-オクタデシルホスファチジルコリン、1-ラウリルプロパンジオール-3-ホスホコリン、エリスロ-N-リグノセロイルスフィンゴホスファチジルコリンおよびパルミトイル-(9-cis-オクタデセノイル)-3-sn-ホスファチジルコリン等が挙げられる。
ホスファチジルセリン類の具体例としては、ジステアロイルホスファチジルセリン(DSPS)、ジミリストイルホスファチジルセリン(DMPS)、ジラウロイルホスファチジルセリン(DLPS)、ジパルミトイルホスファチジルセリン(DPPS)、ジオレオイルホスファチジルセリン(DOPS)、リゾホスファチジルセリン、エレオステアロイルホスファチジルセリンおよび1,2-ジ-(9-cis-オクタデセノイル)-3-sn-ホスファチジルセリン等が挙げられる。
ホスファチジルイノシトール類の具体例としては、ジパルミトイルホスファチジルイノシトール(DPPI)、ジステアロイルホスファチジルイノシトール(DSPI)、およびジラウロイルホスファチジルイノシトール(DLPI)等が挙げられる。
ホスファチジルグリセロール類の具体例としては、ジパルミトイルホスファチジルグリセロール(DPPG)、ジステアロイルホスファチジルグリセロール(DSPG)、ジオレオイルホスファチジルグリセロール(DOPG)、ジラウロイルホスファチジルグリセロール(DLPG)、ジミリストイルホスファチジルグリセロール(DMPG)、リゾホスファチジルグリセロール、水素化大豆ホスファチジルグリセロール(HSPG)、水素化卵ホスファチジルグリセロール(HEPG)およびカルジオリピン(ジホスファチジルグリセロール)等が挙げられる。
ホスファチジルエタノールアミン(セファリン)類の具体例としては、ジパルミトイルホスファチジルエタノールアミン(DPPE)、ジステアロイルホスファチジルエタノールアミン(DSPE)、ジオレオイルホスファチジルエタノールアミン(DOPE)、ジラウロイルホスファチジルエタノールアミン(DLPE)、ジミリストイルホスファチジルエタノールアミン(DMPE)、ジデカノイルホスファチジルエタノールアミン(DDPE)、N-グルタリルホスファチジルエタノールアミン(NGPE)、リゾホスファチジルエタノールアミン、N-(7-ニトロ-2,1,3-ベンゾキシジアゾール-4-イル)-1,2-ジオレオイル-sn-ホスファチジルエタノールアミン、エレオステアロイルホスファチジルエタノールアミン、N-スクシニルジオレオイルホスファチジルエタノールアミンおよび1-ヘキサデシル-2-パルミトイルグリセロホスファチジルエタノールアミン等が挙げられる。なお、後述する製造例7では、マレイミド基を有するジステアロイルホスファチジルエタノールアミン(DSPE)誘導体であるジステアロイルN-(3-マレイミド-1-オキソプロピル)-L-α-ホスファチジルエタノールアミン(日油(株)製、COATSOME(登録商標)FE-8080MA3)を脂質の原料として用いている。このように、部位(I)との連結のためのマレイミド基やスクシンイミド基などの官能基を、8以上の種々の炭素原子数の炭化水素基とともに有するホスファチジルエタノールアミン類(および他の脂質誘導体)もまた、これと同様に用いられうる。
ホスファチジン酸類の具体例としては、ジパルミトイルホスファチジン酸(DPPA)、ジステアロイルホスファチジン酸(DSPA)、ジミリストイルホスファチジン酸(DMPA)およびジオレイルホスファチジン酸(DOPA)等が挙げられる。
スフィンゴリン脂質の具体例としては、例えば、スフィンゴミエリン、ジパルミトイルスフィンゴミエリン、ジステアロイルスフィンゴミエリン、セラミドシリアチン、セラミドホスホリルエタノールアミンおよびセラミドホスホリルグリセロール等が挙げられる。
グリセロ糖脂質の具体例としては、ジグリコシルジグリセリド、グリコシルジグリセリド、ジガラクトシルジグリセリド、ガラクトシルジグリセリド、スルホキシリボシルジグリセリド、(1,3)-D-マンノシル(1,3)ジグリセリド、ジガラクトシルグリセリド、ジガラクトシルジラウロイルグリセリド、ジガラクトシルジミリストイルグリセリド、ジガラクトシルジパルミトイルグリセリド、ジガラクトシルジステアロイルグリセリド、ガラクトシルグリセリド、ガラクトシルジラウロイルグリセリド、ガラクトシルジミリストイルグリセリド、ガラクトシルジパルミトイルグリセリド、ガラクトシルジステアロイルグリセリドおよびジガラクトシルジアシルグリセロール等が挙げられる。
スフィンゴ糖脂質の具体例としては、セラミド(セレブロシド)、ガラクトシルセラミド、ラクトシルセラミド、ジガラクトシルセラミド、ガングリオシドGM1、ガングリオシドGM2、ガングリオシドGM3、スルファチド、セラミドオリゴヘキソシドおよびグロボシドが挙げられる。
その他の糖脂質としては、セラミドオリゴヘキソシド、パルミチルグリコシド、ステアリルグルコシド、ミリスチルグルコシド、アルキルグリコシド、アミノフェニルグリコシド、コレステリルマルトシド、コレステリルグルコシド、3-コレステリル-6’-(グリコシルチオ)ヘキシルエーテル糖脂質およびグルカミド類等が挙げられる。
本発明に係る両親媒性化合物の数平均分子量(Mn)は1000以上であることが好ましく、2000以上であることがさらに好ましく、100000以下であることが好ましく、50000以下であることがさらに好ましい。
本発明に係る両親媒性化合物は、生体適合性が高いことから、医療用途に好適に用いられうる。すなわち、本発明の他の形態によれば、本発明に係る両親媒性化合物を含む医療用樹脂組成物が提供される。この医療用樹脂組成物は、本発明に係る両親媒性化合物からなるものであってもよいし、他の成分をさらに含むものであってもよい。他の成分としては、例えば、水、生理食塩水、医薬的に許容される有機溶媒、コラーゲン、ポリビニルアルコール、ポリビニルピロリドン、カルボキシビニルポリマー、カルボキシメチルセルロースナトリウム塩、ポリアクリル酸ナトリウム、アルギン酸ナトリウム、水溶性デキストラン、カルボキシメチルスターチナトリウム、ペクチン、メチルセルロース、エチルセルロース、キサンタンガム、アラビアゴム、カゼイン、ゼラチン、寒天、ジグリセリン、プロピレングリコール、ポリエチレングリコール、ワセリン、パラフィン、ステアリルアルコール、ステアリン酸、ヒト血清アルブミン、マンニトール、ソルビトール、ラクトース、リン酸緩衝生理食塩水、生体内分解性ポリマー、無血清培地、医薬添加物として許容される界面活性剤、生体内で許容される生理的pH緩衝液などが挙げられる。これらの添加剤は、それぞれ単独で用いてもよく、2種以上が併用されてもよい。
後述する製造例1~7および比較製造例1において製造された重合体の数平均分子量は、ゲルパーミエーションクロマトグラフィー(GPC)により測定した。この際、測定条件は、以下の通りとした。
・測定機器:東ソー(株)製、品番:HLC-8320GPC
・分子量カラム:東ソー(株)製、品番:TSKgel SuperAWM-HとSuperAW2500を2本直列に接続
・溶離液:10mmol/L臭化リチウム添加ジメチルホルムアミド
・検量線用標準物質:ポリスチレン
・測定用溶液の調製:ジメチルホルムアミドに重合体を溶解させて重合体の濃度が0.2質量%の溶液を調製し、当該溶液をフィルターで濾過した後の濾液を使用する。
・測定機器:東ソー(株)製、品番:HLC-8320GPC
・分子量カラム:東ソー(株)製、品番:TSKgel α-Mとα-2500を2本直列に接続
・溶離液:0.2M硝酸ナトリウム水溶液80vol%とアセトニトリル20vol%との混合溶液
・検量線用標準物質:ポリエチレングリコール
・測定用溶液の調製:溶離液に重合体を溶解させて重合体の濃度が0.2質量%の溶液を調製し、当該溶液をフィルターで濾過した後の濾液を使用する。
以下の手法により、重合体の形態を有する両親媒性化合物を製造した。
3方コック付きシュレンク管に、グリセリンモノアクリレート1.0g、4-シアノ-4-(ドデシルスルファニルチオカルボニル)スルファニルペンタノエート0.071g、2,2’-アゾビス(イソブチロニトリル)0.022g、エタノール1.8g、および水0.2gを仕込んだ。次いで、管内部の窒素置換を行い、70℃にて1時間撹拌した。得られた反応液をジエチルエーテル中に滴下し精製することで、末端にアルキル基(n-ドデシル基)を含有するポリグリセリンモノアクリレートを得た。得られた両親媒性化合物(重合体)の数平均分子量は2200であった。このうち、炭素原子数8以上の炭化水素基(n-ドデシル基)の分子量は169.3である。
3方コック付きシュレンク管に、グリセリンモノアクリレート1.0g、4-シアノ-4-(ドデシルスルファニルチオカルボニル)スルファニルペンタノエート0.043g、2,2’-アゾビス(イソブチロニトリル)0.013g、エタノール1.8g、および水0.2gを仕込んだ。次いで、管内部の窒素置換を行い、70℃にて1時間撹拌した。得られた反応液をジエチルエーテル中に滴下し精製することで、末端にアルキル基(n-ドデシル基)を含有するポリグリセリンモノアクリレートを得た。得られた両親媒性化合物(重合体)の数平均分子量は10900であった。このうち、炭素原子数8以上の炭化水素基を含む部位(n-ドデシル基)の分子量は169.3である。
3方コック付きシュレンク管に、グリセリンモノアクリレート1.0g、1-オクタデカンチオール0.098g、2,2’-アゾビス(イソブチロニトリル)0.021g、エタノール2.25g、および水0.25gを仕込んだ。次いで、管内部の窒素置換を行い、80℃にて3時間撹拌した。得られた反応液をジエチルエーテル中に滴下し精製することで、末端にアルキル基(n-オクタデシル基)を含有するポリグリセリンモノアクリレートを得た。得られた両親媒性化合物(重合体)の数平均分子量は4100であった。このうち、炭素原子数8以上の炭化水素基(n-オクタデシル基)の分子量は253.5である。
3方コック付きシュレンク管に、グリセリンモノアクリレート1.0g、1-オクタデカンチオール0.049g、2,2’-アゾビス(イソブチロニトリル)0.014g、エタノール1.8g、および水0.2gを仕込んだ。次いで、管内部の窒素置換を行い、80℃にて3時間撹拌した。得られた反応液をジエチルエーテル中に滴下し精製することで、末端にアルキル基(n-オクタデシル基)を含有するポリグリセリンモノアクリレートを得た。得られた両親媒性化合物(重合体)の数平均分子量は8600であった。このうち、炭素原子数8以上の炭化水素基(n-オクタデシル基)の分子量は253.5である。
3方コック付きシュレンク管に、グリセリンモノメタクリレート1.0g、1-オクタデカンチオール 0.045g、2,2’-アゾビス(イソブチロニトリル)0.013g、エタノール1.6g、およびn-ブタノール0.4gを仕込んだ。次いで、管内部の窒素置換を行い、80℃にて3時間撹拌した。得られた反応液の溶液部をジエチルエーテル中に滴下し精製することで、末端にアルキル基(n-オクタデシル基)を含有するポリグリセリンモノメタクリレートを得た。得られた両親媒性化合物(重合体)の数平均分子量は4100であった。このうち、炭素原子数8以上の炭化水素基(n-オクタデシル基)の分子量は253.5である。
3方コック付きシュレンク管に、グリセリンモノメタクリレート1.0g、1-オクタデカンチオール0.045g、2,2’-アゾビス(イソブチロニトリル)0.013g、エタノール1.6g、およびn-ブタノール0.4gを仕込んだ。次いで、管内部の窒素置換を行い、80℃にて3時間撹拌した。得られた反応液の沈降部をエタノール1.0gに溶解させ、さらにジエチルエーテル中に滴下し精製することで、末端にアルキル基(n-オクタデシル基)を含有するポリグリセリンモノメタクリレートを得た。得られた両親媒性化合物(重合体)の数平均分子量は14000であった。このうち、炭素原子数8以上の炭化水素基(n-オクタデシル基)の分子量は253.5である。
3方コック付きシュレンク管に、グリセリンモノメタクリレート1.0g、4-シアノ-4-(フェニルカルボノチオイルチオ)ペンタン酸0.022g、2,2’-アゾビス(2,4-ジメチルバレロニトリル)0.016g、エタノール0.8g、およびn-ブタノール0.2gを仕込んだ。次いで、管内部の窒素置換を行い、50℃にて30分間撹拌した。得られた反応液をジエチルエーテル中に滴下し精製した。得られた重合体0.2g、プロピルアミン0.25g、水1.0gを仕込み室温にて終夜撹拌し凍結乾燥することで、末端にチオール基を導入したポリグリセリンモノメタクリレートを得た。得られた重合体の数平均分子量は5200であった。
3方コック付きシュレンク管に、N-ビニル-2-ピロリドン1.0g、オクタデカンチオール0.064g、2,2’-アゾビス(イソブチロニトリル)0.018g、エタノール1.6g、およびn-ブタノール0.4gを仕込んだ。次いで、管内部の窒素置換を行い、80℃にて3時間撹拌した。得られた反応液をジエチルエーテル中に滴下し精製することで、末端にアルキル基(n-オクタデシル基)を含有するポリビニルピロリドンを得た。得られた両親媒性化合物(重合体)の数平均分子量は12000であった。このうち、炭素原子数8以上の炭化水素基(n-オクタデシル基)の分子量は253.5である。
水素添加大豆由来ホスファチジルコリン(Avanti Polar Lipids社)17.6mg、およびコレステロール(東京化成工業株式会社)4.7mgを20mLのメタノールに溶解した後、200mL容のナスフラスコに入れ、65℃のウォーターバス中でエバポレートして、脂質膜を形成させた。ここに20w/v%のグルコースを含むPBSを3mL加え、密栓して65℃にて30分間温浴し、水和させて脂質懸濁液とした。この脂質懸濁液をマイクロテストチューブに移し、4倍量のPBSを加えた後、15000×Gで20分間遠心分離して、形成したリポソームを沈殿させた。遠心分離後、上清を捨て、新たにPBSを1mL加えて再懸濁したものを、65℃に温めたエクストルーダー(ポアサイズ0.1μm)で整粒し、脂質当量として12.9mg/mLのリポソーム懸濁液を得た。リポソーム懸濁液の濃度測定はラボアッセイ(商標)りん脂質(富士フイルム和光純薬株式会社)を用い、測定プロトコルは添付のマニュアルに準拠した。
上記製造例4で作製した両親媒性化合物(重合体)である、末端にアルキル基(n-オクタデシル基)を含有するポリグリセリンモノアクリレート(数平均分子量8600)を、2w/v%または4w/v%となるようPBSに溶解して、濃度の異なる重合体溶液を調製した。この重合体溶液のそれぞれと、上記で調製したリポソーム懸濁液とを等体積で混合して10℃にて60分間静置し、両親媒性化合物をリポソームに修飾した。ここでは、リポソームを構成する脂質二重膜に、末端アルキル基含有ポリマーのアルキル基部分が挿入されることで、リポソーム表面が当該ポリマーの親水性部位によって修飾(被覆)されたような構造が得られていると推測される。一方、重合体溶液の替わりに同体積のPBSを混合して反応したものを対照区とした。その後、15000×Gで20分間遠心分離し、上清を除いて未反応の両親媒性化合物を除去し、形成した沈殿をPBSで再懸濁した。ゼータサイザーナノZS(マルバーン・パナリティカル社)で各リポソームの粒子径を測定した。その結果、図1に示すように、対照区ではリポソームの粒子径が160.6±5.2nmであった。これに対し、2w/v%および4w/v%の重合体溶液で修飾したリポソームの粒子径はそれぞれ、174.8±6.5nmおよび174.6±5.5nmであり、両親媒性化合物を用いた修飾による粒子径の増大が確認された。
終濃度10w/v%でウシ胎児血清(FBS)(DSファーマバイオメディカル社)を添加したDMEM培地(ナカライテスク社)を用いてマウス由来線維芽細胞であるL929細胞(DSファーマバイオメディカル社)の培養を行った。5.0×103細胞/cm2となるように100mmセルカルチャーディッシュ(BD Falcon社)に播種し、37℃、5%CO2条件下で培養した。100mmセルカルチャーディッシュで70%コンフルエントの状態まで培養したL929細胞を、0.25w/v%トリプシン/50mM EDTA溶液で処理し、前述の血清添加DMEM培地を添加してトリプシン反応を停止させて、L929細胞懸濁液を得た。0.4w/v%トリパンブルー溶液(富士フイルム和光純薬(株))を用いてL929細胞懸濁液中の細胞数を測定した。細胞懸濁液を1ウェルあたりの細胞数が2.5×103細胞となるよう96ウェルプレート(サーモフィッシャーサイエンス社)に播種し、37℃、5%CO2条件下で24時間培養した。24時間後、各ウェルから培地を50μLずつ除去した後、製造例1~7および比較製造例1で作製した両親媒性化合物(重合体)を2w/v%となるようにPBSに溶解した重合体溶液を各ウェルに50μLずつ加え、37℃、5%CO2条件下で24時間インキュベートした。インキュベート後、各ウェルに細胞増殖キットII(XTT)(シグマアルドリッチ社)試薬を51μLずつ加え、37℃、5%CO2条件下で3時間インキュベートした。その後、プレートリーダーSH-9000(コロナ電気株式会社)で吸光度を測定した。測定プロトコルはキットに添付のマニュアルに準拠した。重合体溶液の替わりにPBSを加えて試験したウェルの測定値と、各サンプルを加えたウェルの測定値を基に、L929細胞の生存率を以下の式から算出した。
その結果、図2に示すように、いずれの重合体溶液もL929細胞の生存率に有意な差を与えず、顕著な細胞毒性は見られなかった。
終濃度10w/v%でウシ胎児血清(FBS)(DSファーマバイオメディカル社)を添加したDMEM培地(ナカライテスク社)を用いてマウス由来線維芽細胞であるL929細胞(DSファーマバイオメディカル社)の培養を行った。5.0×103細胞/cm2となるように100mmセルカルチャーディッシュ(BD Falcon社)に播種し、37℃、5%CO2条件下で培養した。100mmセルカルチャーディッシュで70%コンフルエントの状態まで培養したL929細胞を、0.25w/v%トリプシン/50mM EDTA溶液で処理し、前述の血清添加DMEM培地を添加してトリプシン反応を停止させて、L929細胞懸濁液を得た。0.4w/v%トリパンブルー溶液(富士フイルム和光純薬(株))を用いてL929細胞懸濁液中の細胞数を測定した。細胞懸濁液を1ウェルあたりの細胞数が2.5×103細胞となるよう96ウェルプレート(サーモフィッシャーサイエンス社)に播種し、37℃、5%CO2条件下で24時間培養した。24時間後、各ウェルから培地を50μLずつ除去した。次いで、前述の「リポソームへの両親媒性化合物(重合体)の修飾」の項の記載に従い、上記製造例1~7および比較製造例1で作製した両親媒性化合物(重合体)の2w/v%溶液を用いて得られた修飾リポソーム懸濁液または無修飾リポソーム懸濁液(いずれも5mg-脂質/mL)を50μLずつ加えて、37℃、5%CO2条件下で24時間インキュベートした。インキュベート後、各ウェルに細胞増殖キットII(XTT)(シグマアルドリッチ社)試薬を51μLずつ加え、37℃、5%CO2条件下で3時間インキュベートした。その後、プレートリーダーSH-9000(コロナ電気株式会社)で吸光度を測定した。測定プロトコルはキットに添付のマニュアルに準拠した。修飾リポソーム懸濁液の替わりにPBSを加えて試験したウェルの測定値と、各サンプルを加えたウェルの測定値を基に、L929細胞の生存率を以下の式から算出した。
その結果、図3に示すように、いずれの両親媒性化合物(重合体)を修飾したリポソームもL929細胞の生存率に有意な差を与えず、顕著な細胞毒性は見られなかった。
上記製造例4および製造例6、並びに比較製造例1で作製した両親媒性化合物(重合体)のそれぞれを、1w/v%となるようPBSに溶解して、重合体溶液を調製した。この重合体溶液4.5mLとポリプロピレン(PP)製微粉末(平均粒径5ミクロンメートル)1.5gとをねじ口瓶に入れ、スターラーで30分間撹拌した。撹拌後、それぞれの重合体溶液の重合体濃度を、GPCのピーク面積から定量した。初発の重合体濃度(C0)および試験後の重合体濃度(Ct)から、以下の式を用いて微粉末1gあたりの重合体の吸着量を算出した。結果を下記の表1に示す。
水素添加大豆由来ホスファチジルコリン(Avanti Polar Lipids社)17.6mg、およびコレステロール(東京化成工業株式会社)4.7mgを20mLのメタノールに溶解した後、200mL容のナスフラスコに入れ、65℃のウォーターバス中でエバポレートして、脂質膜を形成させた。ここに20w/v%のグルコースおよび0.02%w/vのフルオレセインイソチオシアネート(FITC)を含むPBSを3mL加え、密栓して65℃にて30分間温浴し、水和させて脂質懸濁液とした。この脂質懸濁液をマイクロテストチューブに移し、4倍量のPBSを加えた後、15000×Gで20分間遠心分離して、形成したリポソームを沈殿させた。遠心分離後、上清を捨て、新たにPBSを1mL加えて再懸濁したものを、65℃に温めたエクストルーダー(ポアサイズ0.1μm)で整粒し、脂質当量として13.7mg/mLのリポソーム懸濁液を得た。リポソーム懸濁液の濃度測定はラボアッセイ(商標)りん脂質(富士フイルム和光純薬株式会社)を用い、測定プロトコルは添付のマニュアルに準拠した。
水素添加大豆由来ホスファチジルコリン(Avanti Polar Lipids社)12.9mg、コレステロール(東京化成工業株式会社)3.4mg、およびPEG-リン脂質(日油(株)製、SUNBRIGHT(登録商標)DSPE-020CN)3.76mgを20mLのメタノールに溶解した後、200mL容のナスフラスコに入れ、65℃のウォーターバス中でエバポレートして、脂質膜を形成させた。ここに20w/v%のグルコースおよび0.02%w/vのFITCを含むPBSを3mL加え、密栓して65℃にて30分間温浴し、水和させて脂質懸濁液とした。この脂質懸濁液をマイクロテストチューブに移し、4倍量のPBSを加えた後、15000×Gで20分間遠心分離して、形成したリポソームを沈殿させた。遠心分離後、上清を捨て、新たにPBSを1mL加えて再懸濁したものを、65℃に温めたエクストルーダー(ポアサイズ0.1μm)で整粒し、脂質当量として9.7mg/mLのリポソーム懸濁液を得た。リポソーム懸濁液の濃度測定はラボアッセイ(商標)りん脂質(富士フイルム和光純薬株式会社)を用い、測定プロトコルは添付のマニュアルに準拠した。
終濃度10w/v%でウシ胎児血清(FBS)(DSファーマバイオメディカル社)を添加したMEM培地(ナカライテスク社)を用いてヒト肝癌由来細胞株であるHepG2細胞(DSファーマバイオメディカル社)の培養を行った。5.0×103細胞/cm2となるように100mmセルカルチャーディッシュ(BD Falcon社)に播種し、37℃、5%CO2条件下で培養した。100mmセルカルチャーディッシュで70%コンフルエントの状態まで培養したHePG2細胞を、0.25w/v%トリプシン/50mM EDTA溶液で処理し、前述の血清添加MEM培地を添加してトリプシン反応を停止させて、HepG2細胞懸濁液を得た。0.4w/v%トリパンブルー溶液(富士フイルム和光純薬株式会社)を用いてHepG2細胞懸濁液中の細胞数を測定した。細胞懸濁液を1ウェルあたりの細胞数が4×104細胞となるよう24ウェルプレート(サーモフィッシャーサイエンス社)に播種し、37℃、5%CO2条件下で48時間培養した。48時間後、各ウェルから培地を除去し、血清を添加していないMEM培地を500μL加えた。次いで、前述の「リポソームへの両親媒性化合物(重合体)の修飾」の項の記載に従い、上記製造例4で作製した両親媒性化合物(重合体)の2w/v%溶液を用いて得られた蛍光物質内封修飾リポソーム懸濁液、または[PEG修飾リポソームの作製]の項の記載に従い作成したPEG修飾リポソーム、または無修飾リポソーム懸濁液(いずれも5mg-脂質/mL)を50μLずつ加えて、37℃または4℃、5%CO2条件下で3時間インキュベートした。インキュベート後、各ウェルの培地を除去し、PBSで2回洗浄した後、0.02w/vのトリトンX-100を含む0.2mol/L水酸化ナトリウム水溶液を350μL加えて細胞を溶解し、プレートリーダーSH-9000(コロナ電気株式会社)で溶解液の蛍光強度を測定した。4℃でインキュベートしたウェルと、37℃でインキュベートしたウェルの測定値を基に、HepG2細胞へのリポソームの取込み量を以下の式から算出した。
次いで、無修飾リポソームとの取込み量の比を以下の式から算出した。
その結果、図4に示すように、PEG修飾リポソームでは無修飾リポソームと比較して細胞への取込み量が有意に減少したのに対し、両親媒性化合物(重合体)を修飾したリポソームでは無修飾リポソームと比較して取込み量に有意な差は見られなかった。
Claims (11)
- 分子内に水酸基を2個以上有し、構成単位の炭素原子のうち側鎖を構成する炭素原子の数が2~10である単量体(a)由来の構成単位(A)を含む部位(I)と、
炭素原子数8以上の炭化水素基と、
を有する、両親媒性化合物。 - 前記部位(I)は、前記単量体(a)由来の構成単位(A)を有する重合体からなる、請求項1に記載の両親媒性化合物。
- 前記炭化水素基の炭素原子数が8~50である、請求項1または2に記載の両親媒性化合物。
- 前記炭化水素基が、直接もしくは二価の結合基を介して前記構成単位(A)を含む部位(I)と結合しているか、または直接もしくは二価の結合基を介して構成単位(A)を含む部位(I)と結合している脂質の一部として存在している、請求項1~3のいずれか1項に記載の両親媒性化合物。
- 前記単量体(a)が単官能の単量体を含む、請求項1~4のいずれか1項に記載の両親媒性化合物。
- 前記炭化水素基が脂質の一部として存在しており、前記脂質の分子量が2000以下である、請求項1~6のいずれか1項に記載の両親媒性化合物。
- 前記構成単位(A)を含む部位(I)の数平均分子量(Mn)が1000~15000である、請求項1~7のいずれか1項に記載の両親媒性化合物。
- 請求項1~8のいずれか1項に記載の両親媒性化合物を含む、医療用樹脂組成物。
- 請求項1~8のいずれか1項に記載の両親媒性化合物を含む、リポソーム。
- 請求項1~8のいずれか1項に記載の両親媒性化合物、請求項9に記載の医療用樹脂組成物または請求項10に記載のリポソームから構成された、医薬品添加剤。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3134852A CA3134852A1 (en) | 2019-03-29 | 2020-03-30 | Amphiphilic compound, and medical resin composition and pharmaceutical additive using the same |
CN202080024959.2A CN113646341B (zh) | 2019-03-29 | 2020-03-30 | 两亲性化合物、以及使用了其的医疗用树脂组合物和药品添加剂 |
CN202310509663.5A CN116589702A (zh) | 2019-03-29 | 2020-03-30 | 两亲性化合物、以及使用了其的医疗用树脂组合物和药品添加剂 |
US17/441,859 US20220185918A1 (en) | 2019-03-29 | 2020-03-30 | Amphiphilic compound, and medical resin composition and pharmaceutical additive using the same |
EP20781875.8A EP3950735A4 (en) | 2019-03-29 | 2020-03-30 | AMPHIPHILE COMPOUND, AND MEDICAL RESIN COMPOSITION AND MEDICINE ADDITIVE EACH USING SUCH AMPHIPHILE COMPOUND |
CN202310509657.XA CN116606393A (zh) | 2019-03-29 | 2020-03-30 | 两亲性化合物、以及使用了其的医疗用树脂组合物和药品添加剂 |
JP2021512133A JP7250907B2 (ja) | 2019-03-29 | 2020-03-30 | 両親媒性化合物、並びにこれを用いた医療用樹脂組成物および医薬品添加剤 |
JP2023045195A JP2023076520A (ja) | 2019-03-29 | 2023-03-22 | 両親媒性化合物、並びにこれを用いた医療用樹脂組成物および医薬品添加剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019-067826 | 2019-03-29 | ||
JP2019067826 | 2019-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020203998A1 true WO2020203998A1 (ja) | 2020-10-08 |
Family
ID=72668997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/014668 WO2020203998A1 (ja) | 2019-03-29 | 2020-03-30 | 両親媒性化合物、並びにこれを用いた医療用樹脂組成物および医薬品添加剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220185918A1 (ja) |
EP (1) | EP3950735A4 (ja) |
JP (2) | JP7250907B2 (ja) |
CN (3) | CN116606393A (ja) |
CA (1) | CA3134852A1 (ja) |
WO (1) | WO2020203998A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023112912A1 (ja) * | 2021-12-15 | 2023-06-22 | 株式会社日本触媒 | コンジュゲート化合物およびコンジュゲート化合物の製造方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10506127A (ja) * | 1995-07-10 | 1998-06-16 | ヘレウス・クルツァ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 芳香族カルボン酸無水物とヒドロキシ(メタ)アクリレートからなる芳香族カルボン酸誘導体、並びにこれらの化合物を含有する配合物 |
JP2003508125A (ja) * | 1999-09-02 | 2003-03-04 | アルコン,インコーポレイテッド | 移植片用の共有結合した親水性塗装組成物 |
WO2008084656A1 (ja) * | 2006-12-22 | 2008-07-17 | Sekisui Chemical Co., Ltd. | ガラスペースト |
JP2010531166A (ja) * | 2007-06-22 | 2010-09-24 | ボーシュ アンド ローム インコーポレイティド | 眼科用溶液 |
JP2019067826A (ja) | 2017-09-28 | 2019-04-25 | キヤノン株式会社 | 撮像装置およびその製造方法ならびに機器 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4529786A (en) * | 1981-03-30 | 1985-07-16 | Celanese Corporation | Acrylate and methacrylate monoesters of pentaerythritol and pentaerythritol orthoesters and polymers and copolymers derived therefrom |
IL162319A0 (en) * | 2001-12-04 | 2005-11-20 | Univ Ben Gurion | Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting |
KR20070052747A (ko) * | 2004-09-10 | 2007-05-22 | 도레이 가부시끼가이샤 | 의약품제제 |
EP2128180A1 (en) * | 2008-05-29 | 2009-12-02 | Unilever N.V. | Amphiphilic branched polymers and their use as emulsifiers |
GB201003970D0 (en) * | 2010-03-10 | 2010-04-21 | Univ Sheffield | Polymer synthesis |
CN103003377B (zh) * | 2010-07-24 | 2016-08-10 | 株式会社日本触媒 | 亲水化处理剂 |
WO2018029462A1 (en) * | 2016-08-08 | 2018-02-15 | The University Of Liverpool | Branched polymers |
-
2020
- 2020-03-30 WO PCT/JP2020/014668 patent/WO2020203998A1/ja unknown
- 2020-03-30 CN CN202310509657.XA patent/CN116606393A/zh active Pending
- 2020-03-30 CN CN202080024959.2A patent/CN113646341B/zh active Active
- 2020-03-30 CN CN202310509663.5A patent/CN116589702A/zh active Pending
- 2020-03-30 EP EP20781875.8A patent/EP3950735A4/en active Pending
- 2020-03-30 US US17/441,859 patent/US20220185918A1/en active Pending
- 2020-03-30 JP JP2021512133A patent/JP7250907B2/ja active Active
- 2020-03-30 CA CA3134852A patent/CA3134852A1/en active Pending
-
2023
- 2023-03-22 JP JP2023045195A patent/JP2023076520A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10506127A (ja) * | 1995-07-10 | 1998-06-16 | ヘレウス・クルツァ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 芳香族カルボン酸無水物とヒドロキシ(メタ)アクリレートからなる芳香族カルボン酸誘導体、並びにこれらの化合物を含有する配合物 |
JP2003508125A (ja) * | 1999-09-02 | 2003-03-04 | アルコン,インコーポレイテッド | 移植片用の共有結合した親水性塗装組成物 |
WO2008084656A1 (ja) * | 2006-12-22 | 2008-07-17 | Sekisui Chemical Co., Ltd. | ガラスペースト |
JP2010531166A (ja) * | 2007-06-22 | 2010-09-24 | ボーシュ アンド ローム インコーポレイティド | 眼科用溶液 |
JP2019067826A (ja) | 2017-09-28 | 2019-04-25 | キヤノン株式会社 | 撮像装置およびその製造方法ならびに機器 |
Non-Patent Citations (2)
Title |
---|
BIOMATERIALS, vol. 25, no. 16, 2004, pages 3259 - 3266 |
J. PHARMACOL. EXP. THER., vol. 292, no. 3, 2000, pages 1071 - 1079 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023112912A1 (ja) * | 2021-12-15 | 2023-06-22 | 株式会社日本触媒 | コンジュゲート化合物およびコンジュゲート化合物の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
CA3134852A1 (en) | 2020-10-08 |
CN116606393A (zh) | 2023-08-18 |
CN116589702A (zh) | 2023-08-15 |
JP7250907B2 (ja) | 2023-04-03 |
JPWO2020203998A1 (ja) | 2020-10-08 |
US20220185918A1 (en) | 2022-06-16 |
JP2023076520A (ja) | 2023-06-01 |
EP3950735A4 (en) | 2023-01-04 |
CN113646341A (zh) | 2021-11-12 |
EP3950735A1 (en) | 2022-02-09 |
CN113646341B (zh) | 2023-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Acid-disintegratable polymersomes of pH-responsive amphiphilic diblock copolymers for intracellular drug delivery | |
Oommen et al. | Multifunctional hyaluronic acid and chondroitin sulfate nanoparticles: impact of glycosaminoglycan presentation on receptor mediated cellular uptake and immune activation | |
JP7513675B2 (ja) | 生体適合性医療用材料 | |
WO2005001070A1 (ja) | 磁性細胞およびその使用方法 | |
Yu et al. | ATRP synthesis of poly (2-(methacryloyloxy) ethyl choline phosphate): a multivalent universal biomembrane adhesive | |
ES2640060T3 (es) | Proceso para producir una partícula fina revestida | |
JP2023076520A (ja) | 両親媒性化合物、並びにこれを用いた医療用樹脂組成物および医薬品添加剤 | |
US20150050330A1 (en) | Compositions and methods for polymer-caged liposomes | |
JPWO2015178343A1 (ja) | siRNA細胞内送達のための脂質膜構造体 | |
Li et al. | Self-assembly of a disulfide-containing core/shell nanocomplex with intracellular environment-sensitive facilitated endo-lysosomal escape for enhanced antitumor efficacy | |
EP2474306A1 (en) | Particle composition and medicinal composition comprising same | |
CN116867500A (zh) | 两性离子脂质纳米颗粒组合物和使用方法 | |
WO2014157606A1 (ja) | 架橋された疎水化多糖ナノゲル粒子とその製造方法 | |
JP6777390B2 (ja) | 生体適合性医療用材料 | |
Khunsuk et al. | Zwitterionic Polymer-Decorated Lipid Nanoparticles for mRNA Delivery in Mammalian Cells | |
JP4723380B2 (ja) | ポリエチレングリコール誘導体及びこれを膜構成成分とする薬物担体 | |
CN114557958A (zh) | 一种刺激响应型聚两性离子纳米凝胶的制备方法与应用 | |
JP7411371B2 (ja) | 糖鎖修飾ポリマーおよびその製造方法、並びにこれを用いた医療用樹脂組成物および医薬品添加剤 | |
Wang et al. | Synthesis of diacylglycerol‐terminated lipid–polymer conjugates: Application to cell surface modification | |
Leiske et al. | Amphiphilic Zwitterionic Bioderived Block Copolymers from Glutamic Acid and Cholesterol–Ability to Form Nanoparticles and Serve as Vectors for the Delivery of 6‐Mercaptopurine | |
WO2001000174A1 (fr) | Liposomes | |
US20240101733A1 (en) | Monoglycerol acrylate based polymer and uses thereof | |
CN117427174B (zh) | 一种用于核酸药物的复合材料及其制备方法和应用 | |
EP4368657A1 (en) | Ph-responsive lipid derivative | |
JP2017226791A (ja) | 樹脂組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20781875 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021512133 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3134852 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020781875 Country of ref document: EP Effective date: 20211029 |